Page last updated: 2024-12-10

alprostadil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5280723
CHEMBL ID495
CHEBI ID15544
SCHEMBL ID33317
MeSH IDM0000811

Synonyms (210)

Synonym
AC-6095
BIDD:GT0747
mr-256
HMS3268I09
BRD-K52459643-001-06-0
gtpl1882
(11alpha,13e,15s)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(13e,15s)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid
pge-1
alprostadilum
muse
11alpha,15alpha-dihydroxy-9-oxo-13-trans-prostenoic acid
caverject
prostin vr
edex
CHEBI:15544 ,
befar
sugiran
alprox-td
prostandin
prostavasin
vitaros
topiglan
u-10136
rayva
femlife
viridal
hei-507
femprox
alista
vasaprostan
3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
prostivas
ono 1608
nsc 165559
ai3-62116
liprostin
cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l-
prostin vr pediatric
lipo-pge1
pge1alpha
l-pge1
alprostadilum [inn-latin]
prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13e,15s)-
(-)-protaglandin e1
l-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
(1r,2r,3r)-3-hydroxy-2-((e)-(3s)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
lipoprost
minprog
prostaglandin e1alpha
einecs 212-017-2
D00180
edex (tn)
prostin vr pediatric (tn)
alprostadil (jp17/usp/inn)
muse (tn)
PRESTWICK3_001018
NCGC00016535-01
cas-745-65-3
PRESTWICK2_001018
SMP2_000271
LMFA03010134
9-oxo-11r,15s-dihydroxy-13e-prostaenoic acid
BSPBIO_001175
BSPBIO_001488
BPBIO1_001293
IDI1_033958
(13e)-(15s)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate
MLS001424250
AB00514004
pge1
745-65-3
alprostadil ,
C04741
(13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoate
prostaglandin e1
nsc165559
(-)-prostaglandin e1
l-prostaglandin e1
u 10136
nsc-165559
u-10,136
alprostadil, meets usp testing specifications
prostaglandin e1, powder, gamma-irradiated, bioxtra, suitable for cell culture
prostaglandin e1, synthetic, powder, bioreagent, suitable for cell culture
smr000112594
MLS000758964
DB00770
NCGC00025234-02
NCGC00025234-03
NCGC00025234-04
NCGC00025234-05
prostaglandin e1, >=98% (hplc), synthetic
HMS2090L08
HMS2052L11
HMS1989K10
CHEMBL495 ,
ono-1608
BML1-F06 ,
HMS1361K10
HMS1791K10
bdbm50101853
HMS1571K17
11,15-dihydroxy-9-oxoprost-13-en-1-oic acidl
A838163
HMS2098K17
7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
BCP9000277
tox21_110482
dtxsid9022578 ,
dtxcid502578
AKOS015961103
CCG-101188
prink
alprostadil prostoglandin e1
cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-
alprostadil [usan:usp:inn:ban:jan]
unii-f5td010360
promostan
f5td010360 ,
caverject impulse
7-[(1r,3r)-3-hydroxy-2-[(1e,3s)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid
XPG ,
alprostadil [inn]
alprostadil [usp-rs]
alprostadil [orange book]
(1r,2r,3r)-3-hydroxy-2-[(e)-(3s)-3-hydroxy-1-octenyl]-5-oxocyclopentaneheptanoic acid
alprostadil [jan]
alprostadil [usp impurity]
alprostadil [usan]
alprostadil [who-dd]
alprostadil [usp monograph]
prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11a,13e,15s)-
alprostadil [mart.]
alprostadil [vandf]
prostaglandin e1 [mi]
S1508
HY-B0131
CS-1905
AB00514004-06
NC00438
SCHEMBL33317
AB00514004-08
(11?,13e,15s)-11,15-dihydroxy-9-oxo-prost-13-en-1-oic acid
W-104416
7-((1r,2r,3r)-3-hydroxy-2-((s,e)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid
prostaglandine1
prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13e,15s)-
7-((1r,2r,3r)-3-hydroxy-2-((s,e)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid
HMS3402K10
HMS3648O17
AB00514004_09
mfcd00077860
prostaglandin e1, >=99.0% (tlc)
SR-01000597593-1
sr-01000597593
SR-01000597593-5
SR-01000597593-6
alprostadil, united states pharmacopeia (usp) reference standard
alprostadil, european pharmacopoeia (ep) reference standard
alprostadil; 7-[(1r,2r,3r)-3-hydroxy-2-[(1e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
HMS3715K17
(-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
(-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
(13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid
alprostadil(usan)
(13e)-(15s)-11,15-dihydroxy-9-oxoprost-13-enoic acid
(+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
11,15-dihydroxy-9-oxoprost-13-en-1-oate
(13e)-(15s)-11,15-dihydroxy-9-oxoprost-13-enoate
3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
prink (tn)
11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (acd/name 4.0)
befar (tn)
(+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
(13e)-(15s)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid
pge1, prostaglandin e1, powder
(11alpha,12alpha,13e,15s)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
Q579348
alprostadil(caverject)
pge1;prostaglandin e1
EX-A1411
HMS3678N07
AS-16360
SR-01000946253-1
sr-01000946253
BCP01740
HMS3414N09
BRD-K52459643-001-17-7
BRD-K52459643-001-10-2
AMY30076
C76381
alprostadil 100 microg/ml in acetonitrile
pge1 (prostaglandin e1)
7-[(1r,2r,3r)-3-hydroxy-2-[(1e,3s)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid
EN300-22411483
prostaglandin e1, pge1, 745-65-3
P1917
7-((1r,2r,3r)-3-hydroxy-2-((1e,3s)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid
alprostadilum (inn-latin)
alprostadil (usp monograph)
g04be01
alprostadil (usp impurity)
prostinvr pediatric
alprostadil (mart.)
alprostadil (usp-rs)
muse (intraurethral alprostadil suppository)
alprostadil (usan:usp:inn:ban:jan)
c01ea01

Research Excerpts

Overview

Alprostadil is a liposomal prostaglandin E1 with beneficial effects on vasodilation, platelet disaggregation and fibrinolysis. It is used to maintain the patency of the ductus arteriosus until palliative or corrective surgery can be performed.

ExcerptReferenceRelevance
"Alprostadil is a commonly used vasodilator, and alpha lipoic acid is an antioxidant, which can effectively reduce oxidative stress responses and delay the progression of diabetes mellitus and its complications."( The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020
)
1.55
"Alprostadil is a kind of liposomal prostaglandin E1 with beneficial effects on vasodilation, platelet disaggregation and fibrinolysis."( Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Ding, S; Ge, H; He, B; He, J; Kong, L; Pu, J; Sheng, X; Sun, Y, 2018
)
1.5
"Alprostadil (lipo-PGE1) is a drug delivery system preparation. "( Specific enhancement of vascular endothelial growth factor (VEGF) production in ischemic region by alprostadil--potential therapeutic application in pharmaceutical regenerative medicine.
Aihara, M; Inoue, H; Tomioka, M; Watabe, Y, 2013
)
2.05
"Alprostadil is a biologically active substance with strong activity on vessel."( Alprostadil liposome microsphere preparation stabilizes vascular plaques and inhibits intra-plaque inflammation.
Chen, L; Cheng, WL; Fan, SY; Guo, J; Guo, YR; Ke, YN; Li, H; Pan, L; Wang, Y, 2012
)
2.54
"Alprostadil is a naturally occurring prostaglandin used in the treatment of infants with congenital heart defects to maintain the patency of the ductus arteriosus until palliative or corrective surgery can be performed. "( Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company).
Roehl, SL; Townsend, RJ, 1982
)
3.15

Effects

ExcerptReferenceRelevance
"Alprostadil has more prominent protective effects against renal I/R injury, while iloprost is superior in terms of protecting the skeletal muscle tissue against I/R injury."( Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia-reperfusion injury in rats.
Arpacı, H; Arslan, M; Çomu, FM; Demirtaş, H; Erer, D; Gönül, İI; Kara, H; Küçük, A; Oktar, GL; Özer, A, 2016
)
1.55

Actions

Alprostadil plays a role in the maintenance and redistribution of intrarenal blood flow and the excretion of electrolytes and water. Alprostadill tended to increase FPA, but this effect did not reach the level of significance (P = 0.07 versus placebo).

ExcerptReferenceRelevance
"Alprostadil plays a role in the maintenance and redistribution of intrarenal blood flow and the excretion of electrolytes and water."( Effect of Alprostadil on the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of 36 Randomized Controlled Trials.
Deng, H; Jiang, M; Li, L; Lin, Y; Xie, J, 2019
)
1.64
"Alprostadil tended to increase FPA, but this effect did not reach the level of significance (P = 0.07 versus placebo)."( Effects of pentoxifylline and alprostadil on ocular hemodynamics in healthy humans.
Dorner, GT; Garhofer, G; Resch, H; Schmetterer, L; Wolzt, M; Zawinka, C, 2007
)
1.35

Treatment

Alprostadil treatment caused a significant decrease in the renal damage parameters. Treatment with al Prostadil achieved satisfactory results with improvement in ulcers, pain, and limb salvage rates in this series of patients.

ExcerptReferenceRelevance
"Alprostadil treats myocardial fibrosis in DM rats by inhibiting the TGF-β1/Smad2 signaling pathway."( Effect of alprostadil on myocardial fibrosis in rats with diabetes mellitus via TGF-β1/Smad signaling pathway.
Dai, Y; Dang, L; Tu, JH; Xu, Y, 2019
)
2.36
"Alprostadil treatment significantly reduced myocardial infarct size, serum troponin T levels, and CK-MB and LDH activity (P<0.05). "( Alprostadil attenuates myocardial ischemia/reperfusion injury by promoting antioxidant activity and eNOS activation in rats.
Sui, D; Xu, H; Yu, X; Zhang, L; Zhang, Y; Zhao, X, 2018
)
3.37
"Alprostadil treatment caused a significant decrease in the renal damage parameters. "( Therapeutic effect of alprostadil in diabetic nephropathy: possible roles of angiopoietin-2 and IL-18.
Chen, Q; Li, T; Li, Z; Liu, J; Luo, C; Wang, Y; Zhang, C, 2014
)
2.16
"Alprostadil treatment can protect renal function by reducing proteinuria."( Therapeutic effect of alprostadil in diabetic nephropathy: possible roles of angiopoietin-2 and IL-18.
Chen, Q; Li, T; Li, Z; Liu, J; Luo, C; Wang, Y; Zhang, C, 2014
)
1.44
"Treatment with alprostadil achieved satisfactory results with improvement in ulcers, pain, and limb salvage rates in this series of patients."( Use of intravenous alprostadil in patients with severe critical ischemia of the lower limbs.
Machado-Alba, JE; Machado-Duque, ME, 2019
)
1.18

Toxicity

Intracavernosal alprostadil is an effective and safe therapy for ED, provided that the individual dose is established by titration, patients are trained in the self-injection technique and supervised periodically. Topical al Prostadil was well tolerated with the most common adverse event being urogenital pain.

ExcerptReferenceRelevance
"Nephrotoxicity is the most troublesome side effect of cyclosporin A (CSA) therapy."( Lack of effect of verapamil and MDL 646, a cytoprotective PGE1 analogue on cyclosporin A nephrotoxicity in vitro.
Hall, TJ; Heckel, C, 1990
)
0.28
" However, continuous iv infusion of this prostaglandin, at dosages which were not severely toxic to the dams, was judged not to be teratogenic or otherwise embryotoxic in rats."( Developmental toxicity of alprostadil in rats after subcutaneous administration or intravenous infusion.
Marks, TA; Morris, DF; Weeks, JR, 1987
)
0.57
"Gastrointestinal symptoms have been the most frequently reported adverse experiences in the misoprostol (Cytotec) studies of both patients with peptic ulcer disease, and healthy subjects."( Focus on misoprostol: review of worldwide safety data.
Wildeman, RA, 1987
)
0.27
" Separated plasma was not toxic towards K562 targets, and failed to potentiate the level of PBMC cytotoxicity through ADCC."( A modified short-term cytotoxicity test: assessment of natural cell-mediated cytotoxicity in whole blood.
Platts, AA; Rees, RC, 1983
)
0.27
" Few data exist on the frequency of adverse effects of prostaglandins in these patients."( Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease.
Altraif, I; Blendis, L; Cattral, MS; Greig, PD; Levy, GA, 1994
)
0.29
" Twenty-three of 25 patients (92%) who received high-dose oral PGE1 or PGE2 incurred arthritis and/or gastrointestinal adverse effects."( Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease.
Altraif, I; Blendis, L; Cattral, MS; Greig, PD; Levy, GA, 1994
)
0.29
"PGE therapy resulted in a wide spectrum of multisystem adverse effects which were reversible with reduction or cessation of therapy."( Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease.
Altraif, I; Blendis, L; Cattral, MS; Greig, PD; Levy, GA, 1994
)
0.29
"The adverse effects of vacuum therapy and intracavernous self-injection in patients on warfarin do not exceed the rate in the general urological population."( Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety.
Donatucci, CF; Henderson, D; Limoge, JP; Olins, E, 1996
)
0.29
" After each home administration, patients recorded in diaries whether or not sexual intercourse occurred and any adverse reactions to the drug."( Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group.
Abbou, CC; Amar, ET; Desvaux, P; Flam, TA; Gesundheit, N; Hall, MM; Lycklama à Nijeholt, GA; Lynch, SF; Morgan, RJ; Müller, SC; Place, VA; Porst, H; Pryor, JP; Ryan, P; Spivack, AP; Williams, G; Witzsch, UK, 1998
)
0.57
" The most common adverse reaction, urethral pain/burning, was reported by 7% of patients in the clinic."( Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group.
Abbou, CC; Amar, ET; Desvaux, P; Flam, TA; Gesundheit, N; Hall, MM; Lycklama à Nijeholt, GA; Lynch, SF; Morgan, RJ; Müller, SC; Place, VA; Porst, H; Pryor, JP; Ryan, P; Spivack, AP; Williams, G; Witzsch, UK, 1998
)
0.57
" The frequency of most adverse effects of radical prostatectomy was comparable to that of other organic etiologies of erectile dysfunction (1,127 patients)."( Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.
Costabile, RA; Fishman, IJ; Gesundheit, N; Govier, FE; Hellstrom, WJ; Nemo, KJ; Rapport, JL; Shabsigh, R; Spevak, M; Tam, PY; Weldon, KL, 1998
)
0.57
" The efficacy and adverse effects were documented."( The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
, 1998
)
0.61
"Intracavernosal alprostadil is an effective and safe therapy for ED, provided that the individual dose is established by titration, patients are trained in the self-injection technique and supervised periodically."( The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
, 1998
)
0.95
" Safety was assessed by clinical evaluation of symptoms and signs of CHF or other adverse events, by catheter-based and echocardiographic search for objective cardiac functional influences, and by echocardiogram monitoring for cardiac rhythm."( Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators.
Bernink, PJ; Borer, JS; Caspi, A; Marmor, A; Rabinowitz, B; Reisin, L; Ruzyllo, W,
)
0.34
"PGE ( 1 ) is safe for treatment of PAOD in patients with concomitant chronic, compensated CHF."( Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators.
Bernink, PJ; Borer, JS; Caspi, A; Marmor, A; Rabinowitz, B; Reisin, L; Ruzyllo, W,
)
0.34
" The most common side effect was penile pain in 25 (29."( Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
Gittleman, M; Goldstein, I; Kaufman, J; McMurray, J; Padma-Nathan, H; Shabsigh, R, 2000
)
0.66
" The efficacy and adverse events were documented."( Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction.
Lin, JS; Lin, YM; Tsai, YS, 2000
)
0.62
" Despite a higher withdrawal rate in this study, intracavernosal alprostadil is still considered as a relatively effective and safe treatment in some diabetic patients with ED if the individual dose is established by titration and patients are trained in the self-injection technique with period supervision."( Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction.
Lin, JS; Lin, YM; Tsai, YS, 2000
)
0.86
" The end results show quite good and the product was satisfactory and safe for all ages."( Evaluation of transurethal alprostadil for safety and efficacy in men with erectile dysfunction.
Kongkanand, A; Luengwattanakit, S; Opanuraks, J; Ratana-Olarn, K; Ruengdilokrat, S; Sripalakit, S; Tantiwong, A; Wuddhikarn, S, 2002
)
0.61
" Topical alprostadil was well tolerated with the most common adverse event being urogenital pain."( The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED.
Harning, R; Padma-Nathan, H; Salem, S; Steidle, C; Tayse, N; Yeager, J, 2003
)
1.01
"38%) discontinued due to adverse events."( [Efficacy and safety of PGE1 cream in the treatment of erectile dysfunction].
Hong, K; Jiang, H; Wang, XF; Xu, QQ; Zhu, JC, 2003
)
0.32
"PGE1 cream is an effective, safe and well-tolerated treatment in subjects with erectile dysfunction of organic, psychologic or mixed etiology."( [Efficacy and safety of PGE1 cream in the treatment of erectile dysfunction].
Hong, K; Jiang, H; Wang, XF; Xu, QQ; Zhu, JC, 2003
)
0.32
" Combination strategies may allow lower drug doses and reduced adverse effects."( Viability and safety of combination drug therapies for erectile dysfunction.
Steers, WD, 2003
)
0.32
"The encouraging preliminary observations combined with the potential for adverse events provide a scientific rationale for prospective, randomized clinical trials with adequate numbers of subjects."( Viability and safety of combination drug therapies for erectile dysfunction.
Steers, WD, 2003
)
0.32
" Adverse events were generally mild or moderate in intensity and mainly involved localized reactions in the genital area."( Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial.
Brown, C; Fendl, J; Harningr, R; Padma-Nathan, H; Salem, S; Yeager, J,
)
0.42
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The most common adverse event was mild, transient genital burning typically < 1 minute duration."( Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy.
Costabile, R; Dietrich, J; Friedman, A; Gittelman, M; Guay, A; Heard-Davison, A; Heiman, JR; Peterson, C; Stephens, D, 2006
)
0.77
" Spontaneous bowel movement (SBM) frequency, rescue medication use, symptom assessments and adverse events (AEs) were tracked."( Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Johanson, JF; Ueno, R, 2007
)
0.34
" There was no evidence of adverse cardio-respiratory effects, bronchial irritation or hypernatremia related to IPGE1."( Toxicity of prolonged high dose inhaled PGE1 in ventilated neonatal pigs.
Chen, X; Dawe, EJ; Galli, R; Maddipati, KR; Malian, M; Rabah, R; Sood, BG, 2008
)
0.35
"In healthy piglets, inhalation of high dose IPGE1 was not associated with adverse cardiorespiratory effects, bronchial irritation, or hypernatremia and produced minimal signs of pulmonary toxicity even after 24h."( Toxicity of prolonged high dose inhaled PGE1 in ventilated neonatal pigs.
Chen, X; Dawe, EJ; Galli, R; Maddipati, KR; Malian, M; Rabah, R; Sood, BG, 2008
)
0.35
"Misoprostol - a stable prostaglandin E1 analogue- is effective and safe in the induction of labour."( Efficacy and safety of misoprostol in induction of labour in a Nigerian tertiary hospital.
Abdul, MA; Ibrahim, UN; Musa, H; Yusuf, MD,
)
0.13
"Safety evaluated patient/partner adverse events (AEs), changes in vital signs, clinical laboratory tests, physical examinations, and electrocardiograms."( Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction.
Mahoney, M; Nelson, M; Pfister, W; Rooney, M; Steidle, C; Yeager, J, 2009
)
0.59
"Topical alprostadil cream was considered effective and safe by most patients and their partners, with most AEs limited to the application site."( Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction.
Mahoney, M; Nelson, M; Pfister, W; Rooney, M; Steidle, C; Yeager, J, 2009
)
1.02
" TRT, the delivery of therapeutic agents directly to the kidneys by renal arterial infusion, has the advantage of providing a higher local effective dose with potentially greater renal effects, while limiting systemic adverse effects due to renal first-pass elimination."( Safety and performance of targeted renal therapy: the Be-RITe! Registry.
Allie, DE; Cohen, MG; Danna, P; Fearon, WF; Filby, SJ; Findeiss, L; Kyriazis, D; Leon, MB; Mehran, R; Moses, JW; Price, MJ; Sachdev, N; Teirstein, PS; Vora, K; Walker, CM; Weinstock, BS; Weisz, G; Wiechmann, BN, 2009
)
0.35
" Gastrointestinal-related disorders were the most common adverse events in both treatment groups."( Efficacy and safety of lubiprostone in patients with chronic constipation.
Barish, CF; Drossman, D; Johanson, JF; Ueno, R, 2010
)
0.36
" The present study was designed to explore the toxic effect of MG on renal proximal tubular cells as well as the protective effect of antioxidants PGE1 and probucol against MG-induced apoptosis in renal proximal tubular cells."( Methylguanidine cytotoxicity on HK-2 cells and protective effect of antioxidants against MG-induced apoptosis in renal proximal tubular cells in vitro.
Jiang, YS; Ling, GH; Wang, F; Yang, B; Yao, C, 2010
)
0.36
" It is concluded that self-intracavernous injection of PGE1 is a safe and effective treatment for ED with various aetiologies and a broad range of severity, and no serious complications were observed after long-term application."( Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China.
Chen, H; He, L; Jiang, X; Tang, Y; Wen, J, 2011
)
0.37
" Adverse events (AEs) were recorded."( Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
Johanson, JF; Lembo, AJ; Miner, PB; Parkman, HP; Rao, SS; Ueno, R, 2011
)
0.37
"The present review has several objectives, the first of which is to review the pharmacology and selectivity of serotonergic agents to contrast the older serotonergic agents (which were withdrawn because of cardiac or vascular adverse effects) with the newer generation serotonin receptor subtype 4 agonists."( New treatment options for chronic constipation: mechanisms, efficacy and safety.
Camilleri, M, 2011
)
0.37
" The primary objective was the assessment of long-term safety and tolerability, monitored via adverse events (AEs), laboratory parameters and vital signs."( Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
Chey, WD; Drossman, DA; Johanson, JF; Panas, RM; Scott, C; Ueno, R, 2012
)
0.38
"In patients with irritable bowel syndrome with constipation, lubiprostone 8 mcg twice daily was found to be safe and well tolerated over 9-13 months of treatment."( Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
Chey, WD; Drossman, DA; Johanson, JF; Panas, RM; Scott, C; Ueno, R, 2012
)
0.38
" It is generally considered to be safe and effective."( Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
Chamberlain, SM; Rao, SS, 2012
)
0.38
" This makes it suitable in any circumstances and results in a reduced risk of adverse events (AEs), being systemic AEs reported in only 3% of the treated population."( Clinical efficacy and safety of Vitaros©/Virirec© (Alprostadil cream) for the treatment of erectile dysfunction.
Cuzin, B; Moncada, I,
)
0.38
" The most common adverse effect was urethral burning, which occurred in 24 patients (29%)."( Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
Conde Caturla, P; Fernández Arjona, M; Garrido Abad, P; Martínez Blázquez, L; Sinués Ojas, B, 2015
)
0.69
" The outcomes measured were as follows: clinical efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV, peroneal SNCV and adverse effects."( Efficacy and safety of prostaglandin E1 plus lipoic acid combination therapy versus monotherapy for patients with diabetic peripheral neuropathy.
Jiang, DQ; Li, MX; Ma, YJ; Wang, Y, 2016
)
0.43
"Liposomal prostaglandin E1 agonist did not cause any apparent neurologic abnormalities in the spinal cord or dorsal root ganglion, suggesting it is neurologically safe for epidural injection in this species."( The Neurological Safety of an Epidurally Administered Lipo-PGE1 Agonist in Rats.
Choe, G; Choi, E; Im, SM; Kim, YH; Lee, PB; Nahm, FS; Yoo, HS,
)
0.13
" Those of us in healthcare, however, can become traumatized when a poor or unanticipated adverse outcome occurs, leading to morbidity and/or mortality, and where one personally bears the responsibility."( Musing onleadership, quality and safety, and burnout: what goes up must come down.
Koyle, MA, 2020
)
0.56
"01 µg/kg/minute is a safe and effective therapy for critical CHD."( Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines?
Baffa, JM; Behere, S; Spurrier, E; Tsuda, T; Vari, D; Xiao, W, 2021
)
0.62
" Safety endpoints included incidence of treatment-emergent adverse events (TEAEs) and changes from baseline in clinical laboratory parameters and vital signs."( Safety of Lubiprostone in Pediatric Patients With Functional Constipation: A Nonrandomized, Open-Label Trial.
Clifford, R; Hussain, SZ; Labrum, B; Mareya, S; Stripling, S, 2021
)
0.62
" Subgroup analyses assessed an impact of age, sex, and race categories on TEAEs and treatment-related adverse events."( Safety of Lubiprostone in Pediatric Patients With Functional Constipation: A Nonrandomized, Open-Label Trial.
Clifford, R; Hussain, SZ; Labrum, B; Mareya, S; Stripling, S, 2021
)
0.62
" Patients who experienced adverse events (AEs) had their dose reduced to 12 mcg twice daily (for 4 weeks)."( Analysis of the impact on efficacy of lubiprostone dose reduction to manage adverse events in the treatment of chronic constipation in Japan.
Kanzo, T; Kimura, T; Kiuchi, M; Nagazumi, A; Ohbayashi, H; Sato, Y, 2022
)
0.72
" According to the obtained results, MP was found to be quite effective in the protection of kidneys from the toxic effects of AK."( Prevention of nephrotoxicity induced by amikacin: The role of misoprostol, A prostaglandin E1 analogue.
Azırak, S, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"The effects of prostaglandin E1 (PGE1) and trimetaphan (TMP) on the plasma concentrations and derived pharmacokinetic parameters of bupivacaine were studied in 14 women after its epidural administration."( [Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension].
Hamakawa, T; Sakimura, S; Takasaki, M; Takeshita, M, 1992
)
0.28
" Pharmacokinetic parameters of these drugs were obtained by using two-compartment open model and population pharmacokinetics."( [Effects of prostaglandin E1 on vecuronium and fentanyl pharmacokinetics in humans].
Ishii, T; Johno, I; Moriyama, S, 1991
)
0.28
" Misoprostol had no significant effect on the t/2, Cmax or AUC of propranolol either after a single dose or at steady state."( Misoprostol does not alter the pharmacokinetics of propranolol.
Bennett, PN; Fenn, GC; Lee, CE; Notarianni, LJ, 1991
)
0.28
" Pharmacokinetic variable values in elderly subjects did not differ in a clinically significant manner from those in younger subjects."( Pharmacokinetics of misoprostol in the elderly, in patients with renal failure and when coadministered with NSAID or antipyrine, propranolol or diazepam.
Karim, A; Nicholson, PA; Smith, M, 1990
)
0.28
"Low misoprostol dose (microgram range), extremely low plasma levels (pg range) of misoprostol acid, and the necessity of using a complex, time consuming, and labor intensive RIA method of analysis make it technically difficult to study the pharmacokinetic profile of misoprostol in man."( Antiulcer prostaglandin misoprostol: single and multiple dose pharmacokinetic profile.
Karim, A, 1987
)
0.27
" The plasma half-life and area under the plasma concentration-time curve of antipyrine were unchanged."( Potential drug interactions with misoprostol: effects on the pharmacokinetics of antipyrine and propranolol.
Bennett, PN; Fenn, GC; Notarianni, LJ, 1988
)
0.27
" The data were adequately described by first-order pharmacokinetic equations which assumed that the lung was the only site of PGE1 clearance."( Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome.
Andreadis, NA; Bone, RC; Cox, JW; Maunder, RJ; Pullen, RH; Ursprung, JJ; Vassar, MJ, 1988
)
0.27
" Pharmacokinetic parameters were calculated for four experimental designs including single-dose bolus injections (30, 10, and 3 micrograms PGE1/kg): single-dose, 4-h continuous infusions (20 and 320 ng/kg/min): multiple-dose continuous infusions (5, 20, 80, and 320 ng/kg/min); and single-dose, 30-day chronic infusions (100 ng/kg/min)."( In vivo disposition of prostaglandin E1 via pharmacokinetic characterization of its pulmonary metabolite.
Bothwell, W; Daniels, EG; Fitzpatrick, FA; Verburg, M,
)
0.13
" For example, plasma levels of the pulmonary metabolite can be quantitated and used as an index of the pharmacokinetic disposition of PGE2 because its metabolite forms almost instantaneously and completely, in vivo."( A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics.
Bothwell, W; Daniels, EG; Fitzpatrick, FA; Verburg, M; Wynalda, M, 1982
)
0.26
" Within the dose range of 30-120 micrograms PGE1 2 h-1 there was a linear increase of Cmax and AUC with the dose."( Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.
Bonn, R; Cawello, W; Leonhardt, A; Lomeli, AL; Schweer, H; Seyberth, HW, 1995
)
0.56
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3
" In amniotic fluid the half-life was between 31 and 37 hours."( Pharmacokinetics of prostaglandins.
Bygdeman, M, 2003
)
0.32
" In the pharmacodynamic study using a cat, alcoholic hydrogel with limonene or cineole showed a significant effect in terms of increasing intracavernosal pressure compared to control hydrogel."( In vitro skin penetration and pharmacodynamic evaluation of prostaglandin E1 ethyl ester, a vasoactive prodrug of prostaglandin E1, formulated into alcoholic hydrogels.
Choi, HG; Choi, SU; Choi, YW; Lee, J; Park, HS; Yang, SW; Yong, CS, 2006
)
0.33
" The hypotensive effect of PGE, was used as an index of drug efficacy, pharmacodynamic parameters such as time to reach peak effect (Tmax), maximal percentage of blood pressure decrease (Emax, %), duration of effect (Td), and the area under the blood pressure decrease percent-time curves (AUC, % x min) were determined after PGE1 given to rats intranasally, sublingually, intraperitoneally (ip), and intramuscularly (im), separately, and compared with those obtained from intravenous (iv) administration."( Pharmacodynamic comparison of prostaglandin E1 administered by different routes to rats.
Cui, FD; Gao, YL; Gu, FG, 2007
)
0.34
"This review outlines the regulatory history, pharmacokinetic, pharmacodynamic and safety data in the treatment of IBS-C with a European perspective."( Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
De Ponti, F; Raschi, E, 2014
)
0.4
"Although interesting pharmacodynamic data suggest that lubiprostone may have additional mechanisms of action, its beneficial effects in IBS-C must be confirmed in the actual clinical scenario taking into account the new version of European Medicines Agency's guideline."( Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
De Ponti, F; Raschi, E, 2014
)
0.4
"50 min) and eliminated (elimination half-life [t ½] = 21."( Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects.
Cao, Y; Chen, H; Ding, Y; Gu, J; Li, X; Liu, C; Sun, Y; Yin, L; Zhang, H; Zhang, Q, 2015
)
0.42

Compound-Compound Interactions

Alprostadil combined with the α-lipoic acid in treating type 2 diabetes mellitus with erectile dysfunction (DMED). Based on conventional therapy with the same oral medicines in the control group.

ExcerptReferenceRelevance
"We performed a double-blind, crossover study using objective measurements to compare maximum rigidity and duration of erections with papaverine hydrochloride in combination with phentolamine mesylate and/or prostaglandin E1."( Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
Allen, RP; Brendler, CB; Engel, RM; Smolev, JK, 1992
)
0.28
" A randomised study was carried out to determine the efficacy of mifepristone and dilapan in combination with gemeprost for second trimester termination between 12-18 weeks' gestation."( A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy.
Baird, DT; Thong, KJ, 1992
)
0.28
" We believe duplex echo-Doppler combined with intracavernal PGE 1 to be a very reliable method in the diagnosis of impotence of a vascular origin."( [Echo-Doppler duplex combined with intracavernous injection of prostaglandin E1 in the diagnosis of impotence].
Basquero González, B; Concejo, J; Díez Cordero, JM; Escribano Patiño, G; Hernández Fernández, C; Herranz Amo, F; Jara Rascon, J; Martin Martínez, JC; Moncada Iribarren, I; Verdú Tartajo, F,
)
0.13
" This vasoactive drug combination has been used in 116 patients for diagnostic testing and subsequent treatment."( An improved vasoactive drug combination for a pharmacological erection program.
Barada, JH; Bennett, AH; Carpenter, AJ, 1991
)
0.28
" prostaglandin E1 in combination with papaverine (although the difference is not statistically significant)."( Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
Floth, A; Schramek, P, 1991
)
0.28
" The antiulcer effect of the drug combination was additive, suggesting that each compound acts independently to prevent gastric bleeding."( Antiulcer effect of rioprostil, a prostaglandin E1 analog, in combination with antacid.
Genna, T; Katz, LB; Shriver, DA, 1986
)
0.27
"Abortion was attempted in 39 women in early pregnancy (less than 56 days amenorrhea) with the progesterone antagonist RU486 alone (150 mg per day for 4 days) or in combination with a PG analogue, 16,16-dimethyl-trans-delta 2-PGE1 (Gemeprost) in the form of a 1 mg vaginal pessary."( Therapeutic abortion in early pregnancy with antiprogestogen RU486 alone or in combination with prostaglandin analogue (gemeprost).
Baird, DT; Cameron, IT; Michie, AF, 1986
)
0.27
"Abortion was attempted in 39 women in early pregnancy (less than 56 days amenorrhea) with the progesterone antagonist RU486 alone (150 mg per day for 4 days) or in combination with a PG analogue, 16,16-dimethyl-trans-delta2-PGE1 (Gemeprost) in the form of a 1 mg vaginal pessary."( Therapeutic abortion in early pregnancy with antiprogestogen RU486 alone or in combination with prostaglandin analogue (gemeprost).
Baird, DT; Cameron, IT; Michie, AF, 1986
)
0.27
" Two cases with either stage III or IV neuroblastoma, whose tumors had not been extirpated at the initial operation, were treated by intra-aortic PGE1 infusion combined with oral papaverine and conventional anti-malignant chemotherapy."( [Intra-aortic PGE1 infusion combined with anti-malignant chemotherapy in the treatment of advanced neuroblastoma].
Hayakawa, K; Inoue, S; Munakata, H; Nara, K; Ono, K; Sato, S; Takahashi, K, 1985
)
0.27
"Mifepristone (600 mg) in combination with a prostaglandin has been demonstrated to be a safe, acceptable alternative to vacuum aspiration for induction of abortion in the first 9 weeks of pregnancy."( Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
Baird, DT; Sukcharoen, N; Thong, KJ, 1995
)
0.29
" The authors' previous research had indicated there is no difference in clinical efficacy between 200 mg and 600 mg (standard dose) of mifepristone in combination with 600 mcg of misoprostol."( Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
Baird, DT; Sukcharoen, N; Thong, KJ, 1995
)
0.29
"A prospective randomized study was conducted to compare the efficacy of misoprostol with gemeprost when combined with mifepristone for termination of second trimester pregnancy."( Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial.
Chan, YF; Ho, PC; Lau, W, 1996
)
0.29
"Findings are presented from a prospective randomized study conducted to compare the efficacy of misoprostol with gemeprost when combined with mifepristone to terminate second trimester pregnancy."( Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial.
Chan, YF; Ho, PC; Lau, W, 1996
)
0.29
"Two regimens of the prostaglandin E1 analogue, gemeprost, in combination with mifepristone were compared in a randomised trial for termination of pregnancy between 12-19 weeks."( A randomised study of two doses of gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy.
Baird, DT; Lynch, P; Thong, KJ, 1996
)
0.29
"Two regimens of prostaglandin E1 analogue, gemeprost, in combination with mifepristone were compared in a randomized trial for termination of pregnancy at 12-19 weeks."( A randomised study of two doses of gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy.
Baird, DT; Lynch, P; Thong, KJ, 1996
)
0.29
"To evaluate the catecholamine and renin-angiotensin response during controlled hypotension combined with hemodilution in the clinical setting."( Catecholamine and renin-angiotensin response during controlled hypotension induced by prostaglandin E1 combined with hemodilution during isoflurane anesthesia.
Fukusaki, M; Hara, T; Kobayashi, I; Maekawa, T; Sumikawa, K, 1997
)
0.3
" The role of platelet-activating factor (PAF) in the pathophysiology of ischemia-reperfusion injury and the protective effect of a novel phospholipid PAF analog (TCV-309) alone and combined with prostaglandin E1 (PGE1) is investigated in an extended (20 hours) ex vivo lung preservation."( Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1.
Ansley, DM; Duncan, S; English, JE; Fradet, G; Nikbakht-Sangari, M; Pearson, B; Qayumi, AK; Sammartino, C, 1997
)
0.3
"To evaluate the effect of controlled hypotension combined with hemodilution on gastric intramural pH in the clinical setting."( Effect of controlled hypotension combined with hemodilution on gastric intramural pH.
Cho, S; Fukusaki, M; Hara, T; Maekawa, T; Nakamura, T; Sumikawa, K, 1998
)
0.3
"The results suggest that moderate hemodilution, such as 23% of hematocrit value, might impair oxygenation in gastrointestinal mucosa, whereas controlled hypotension induced by PGE1 combined with the hemodilution would not increase this impairment."( Effect of controlled hypotension combined with hemodilution on gastric intramural pH.
Cho, S; Fukusaki, M; Hara, T; Maekawa, T; Nakamura, T; Sumikawa, K, 1998
)
0.3
"Mifepristone in combination with prostaglandin has been used since 1988 for induction of early abortion."( Interruption of early pregnancy with mifepristone in combination with gemeprost.
Brooks, L; Grinsted, J; Grinsted, L; Jacobsen, JD; Nielsen, SP; Sandstrøm, O; Schantz, A, 1999
)
0.3
" Patients were treated with sildenafil citrate alone or in combination with intracavernosal injection therapy."( Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy.
Johnson, H; McMahon, CG; Samali, R, 1999
)
0.3
" Sildenafil in combination with intracavernosal injection is associated with a 33% incidence of adverse effects, including a 20% incidence of dizziness."( Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy.
Johnson, H; McMahon, CG; Samali, R, 1999
)
0.3
" A composite thrombolytic treatment using low-dose rt-pa in combination with PGE1 offers significantly better results than an acute thrombolytic treatment alone."( Retrospective analysis of Rt-pa thrombolysis combined with PGE1 in patients with peripheral arterial occlusions.
Buss, C; Kröger, K; Rudofsky, G, 2000
)
0.31
" Ten days after injection, cisplatin (5 mg/kg) was administered with PGE1 to 20 and the remaining 20 were injected with physiological saline."( Cisplatin combined with prostaglandin E1 chemotherapy in rat peritoneal carcinomatosis.
Ikeguchi, M; Kaibara, N; Maeta, M, 2000
)
0.31
"To evaluate the effect of controlled hypotension combined with acute hypervolemic or normovolemic hemodilution on the splanchnic perfusion in the clinical setting."( Splanchnic perfusion during controlled hypotension combined with acute hypervolemic hemodilution: a comparison with combination of acute normovolemic hemodilution-gastric intramucosal pH study.
Fukusaki, M; Miyoshi, H; Nakamura, T; Sumikawa, K; Tamura, S, 2000
)
0.31
" Controlled hypotension with prostaglandin E1 would not impair splanchnic perfusion in combination with either HHD or ANH."( Splanchnic perfusion during controlled hypotension combined with acute hypervolemic hemodilution: a comparison with combination of acute normovolemic hemodilution-gastric intramucosal pH study.
Fukusaki, M; Miyoshi, H; Nakamura, T; Sumikawa, K; Tamura, S, 2000
)
0.31
"Gemeprost and misoprostol are two of the most widely used prostaglandins in combination with mifepristone for medical abortion in early pregnancy."( Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation.
Baird, DT; Bartley, J; Brown, A; Elton, R, 2001
)
0.31
"Experience of clinical treatment of 9 patients with diabetes mellitus and diabetic angiopathy using alprostan in combination with rays "Bioptron-II" and iruxol-miramistinum in conditions of polyclinic was summarized."( [Clinical efficacy of alprostan in combination with "Bioptron-II" rays and iruxol-miramistin in the treatment of the diabetic foot complicated by atherosclerosis].
Tomashuk, II; Tomashuk, IP, 2001
)
0.31
"To compare the effectiveness of gemeprost and misoprostol as prostaglandins used in combination with mifepristone for induction of mid-trimester termination."( A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy.
Baird, DT; Bartley, J, 2002
)
0.31
"To assess magnetic resonance imaging (MRI) combined with artificial erection for local staging of penile cancer."( Magnetic resonance imaging combined with artificial erection for local staging of penile cancer.
Bonomo, G; de Cobelli, O; Matei, DV; Rocco, B; Scardino, E; Varela, R; Verweij, F; Villa, G, 2004
)
0.32
"To assess the value of visual sexual stimulation combined with intracavernous injections (ICI) in patients treated for severe erectile dysfunction."( [Evaluation of visual stimulation combined with intracavernous injections for the treatment of severe erectile dysfunction].
Beley, S; Chartier-Kastler, E; Galiano, M; Gattegno, B; Richard, F; Rouprêt, M, 2007
)
0.34
" The outpatient protocol consisted of comparing the efficacy of alprostadil ICI alone on D0 and ICI combined with erotic stimulation on D8."( [Evaluation of visual stimulation combined with intracavernous injections for the treatment of severe erectile dysfunction].
Beley, S; Chartier-Kastler, E; Galiano, M; Gattegno, B; Richard, F; Rouprêt, M, 2007
)
0.58
"Visual sexual stimulation has not been demonstrated to be truly effective in the hospital setting in combination with intracavernous injections."( [Evaluation of visual stimulation combined with intracavernous injections for the treatment of severe erectile dysfunction].
Beley, S; Chartier-Kastler, E; Galiano, M; Gattegno, B; Richard, F; Rouprêt, M, 2007
)
0.34
" The purpose of this study is to evaluate effects of CHP nanogels in combination with prostaglandin E1 on wound healing in full thickness skin defect model."( Effects of cholesterol-bearing pullulan (CHP)-nanogels in combination with prostaglandin E1 on wound healing.
Akiyoshi, K; Kasugai, S; Katakura, O; Kobayashi, H; Morimoto, N, 2009
)
0.35
"We aimed to assess the efficacy and safety of midtrimester termination of pregnancy using gemeprost in combination with laminaria in women who had previously undergone cesarean section and in women who had not."( Midtrimester termination of pregnancy using gemeprost in combination with laminaria in women who have previously undergone cesarean section.
Abe, K; Fujiki, Y; Hamada, H; Nakamura, Y; Obata-Yasuoka, M; Ogura, T; Shimura, R; Takeshima, K; Toyoda, M; Watanabe, H; Yagi, H; Yoshikawa, H, 2009
)
0.35
"Aprotinin combined with NO and PGE(1) produced synergistic protective effects and improved renal function, due partly to inhibition of platelet and neutrophil activation and suppression of thrombin formation."( Aprotinin combined with nitric oxide and prostaglandin E1 protects the canine kidney from cardiopulmonary bypass-induced injury.
An, Q; Du, L; Lin, K; Liu, J; Tang, J; Tao, K; Wu, X; Zhou, J, 2010
)
0.36
"Medical regimens using mifepristone in combination with prostaglandins have been widely available for women undergoing termination of pregnancy (TOP) at 10-16 weeks' gestation in China."( Mifepristone in combination with prostaglandins for termination of 10-16 weeks' gestation: a systematic review.
Chen, QJ; Cheng, LN; Hong, QQ; Hou, SP; Huang, YM; Meads, C; Zhu, HP, 2011
)
0.37
"In combination with osmotic dilators and gemeprost, gestational age and parity are independent factors that affected the induction to abortion interval of second-trimester medical abortion."( Effects of parity and gestational age on second-trimester induction-abortion interval in combination with osmotic dilators and gemeprost.
Kai, K; Karakida, S; Kono, M; Narahara, H; Nishida, Y; Sasaki, T; Togo, K; Tsuno, A, 2012
)
0.38
"Effects of traditional Chinese medicine salvianolate combined with alprostadil and reduced glutathione on delay of progression in patients with acute kidney injury has been confirmed, but the role of this combination therapy on the progression of chronic renal failure is uncertain."( [Effects of salvianolate combined with alprostadil and reduced glutathione on progression of chronic renal failure in patients with chronic kidney diseases: a long-term randomized controlled trial].
Cui, RL; Fu, P; Huang, XQ; Mei, XB; Yu, G; Yuan, AH, 2012
)
0.88
"To investigate the long-term effects of regular administration of salvianolate combined with Western medicine on the progression of chronic renal failure in patients with chronic kidney diseases (CKDs)."( [Effects of salvianolate combined with alprostadil and reduced glutathione on progression of chronic renal failure in patients with chronic kidney diseases: a long-term randomized controlled trial].
Cui, RL; Fu, P; Huang, XQ; Mei, XB; Yu, G; Yuan, AH, 2012
)
0.65
"To investigate the effect of prostaglandins E1 combined with Xuebijing injection on the expression of transforming growth factor-β₁ (TGF-β₁) and tumor necrosis factor-α (TNF-α) in rats with acute pulmonary interstitial fibrosis."( [Effect of prostaglandin E1 combined with Xuebijing injection on transforming growth factor-β₁ in rats with pulmonary interstitial fibrosis].
Li, ZJ; Zhang, WX, 2012
)
0.38
"Prostaglandin E1 combined with Xuebijing injection may significantly inhibit TGF-β₁ expression in the lung tissue of rats with acute pulmonary interstitial fibrosis, which reduces alveolar inflammatory response."( [Effect of prostaglandin E1 combined with Xuebijing injection on transforming growth factor-β₁ in rats with pulmonary interstitial fibrosis].
Li, ZJ; Zhang, WX, 2012
)
0.38
"Intravenous alprostadil in combination with oral statins is superior to statins alone for protecting renal function in patients with mild to moderate renal dysfunction who undergo coronary angiography, and can reduce the incidence of adverse events seen within six months."( Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography.
Guo, R; Li, WM; Liu, WJ; Wei, YD; Xu, YW; Zhang, BC, 2013
)
1.07
" We searched published randomized controlled trials (RCTs) of PGE1 combined with MC for DPN up to June 1, 2013."( Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy.
Deng, H; Ji, A; Liu, L; Liu, X; Wu, Z; Xu, Q; Yin, J; Zhang, J, 2014
)
0.4
"To investigate the protective effect of target temperature management (TTM) combined with prostaglandin E₁ (PGE₁) on ischemia/reperfusion (I/R) injury of cerebral micro-vascular endothelium cell (CMEC) in the return of spontaneous circulation (ROSC) rats with successful cardiopulmonary resuscitation."( [The Protective Effect of Target Temperature Management Combined with Prostaglandin E₁ on Ischemia/Reperfusion Injury of Cerebral Micro-vascular Endothelium of ROSC Rat].
He, YR; Hu, H; Lai, SC; Liu, BF; Wan, Z; Wei, W; Xie, Y, 2016
)
0.43
"We investigated the clinical value of alprostadil combined with the α-lipoic acid in treating type 2 diabetes mellitus with erectile dysfunction (DMED)."( Study on the clinical value of alprostadil combined with α-lipoic acid in treatment of type 2 diabetes mellitus patients with erectile dysfunction.
Huang, FC; Huang, Q; Li, JR; Liu, C; Zhang, HY; Zhang, L, 2016
)
0.99
"Alprostadil combined with α-lipoic acid can improve DMED patients' vascular endothelial function and erection hardness to treat erectile dysfunction with less adverse effects and better safety."( Study on the clinical value of alprostadil combined with α-lipoic acid in treatment of type 2 diabetes mellitus patients with erectile dysfunction.
Huang, FC; Huang, Q; Li, JR; Liu, C; Zhang, HY; Zhang, L, 2016
)
2.16
"To evaluate the clinical efficacy of Panax notoginseng extract combined with alprostadil in the treatment of arteriosclerosis occlusion and investigate its effects on the degree of atherosclerosis."( [Panax notoginseng extract combined with alprostadil in treatment of arteriosclerosis obliterans: Meta-analysis].
, 2018
)
0.98
"To observe the clinical curative effects of alprostadil combined with calcium dobesilate in type 2 diabetes patients with peripheral neuropathy."( Effects of alprostadil combined with calcium dobesilate in patients with diabetic peripheral neuropathy.
Han, K; Liu, C; Rao, X; Shi, X, 2018
)
1.13
" However, there is a lack of evidence-based medical evidence for alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy, and this article aims to understand the clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropath by a meta-analysis of published randomized controlled trials."( The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020
)
1.06
" Retrieving a randomized controlled study of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropath, while the language of the literature is restricted and it only includes Chinese and English literature."( The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020
)
1.08
"This study will draw reliable evidence-based medical evidence for alprostadil combined with Alpha lipoic acid in the treatment of diabetic peripheral neuropathy, thus providing help for the clinical treatment of diabetic peripheral neuropathy."( The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis.
Fang, C; Fang, X; Guan, H; Han, P; Li, L; Qiu, S; Ye, M; Zhang, L, 2020
)
1.06
" However, the effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) are still not fully clear."( Effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in AMI patients after PCI.
Liu, X; Lu, Y; Yan, Y, 2021
)
1.31
" The group A was treated with alprostadil, the group B was treated with tanshinone IIa injection, and the group C was treated with alprostadil combined with tanshinone IIa injection."( Effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in AMI patients after PCI.
Liu, X; Lu, Y; Yan, Y, 2021
)
1.3
"For AMI patients after PCI, alprostadil combined with tanshinone IIa injection can effectively improve microcirculation and ventricular remodeling, improve cardiac function and reduce the occurrence of MACEs."( Effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in AMI patients after PCI.
Liu, X; Lu, Y; Yan, Y, 2021
)
1.31
"This study aims to investigate the effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy (DN) and its effect on serum miR-126 and miR-342 levels."( Effect of hyperbaric oxygen combined with alprostadil in the treatment of elderly diabetic nephropathy and effects on serum miR-126 and miR-342 levels.
Han, X; Xi, W; Yang, X; Zhou, Y, 2021
)
1.11
"The study aimed to explore the roles of alprostadil combined with edaravone in inflammation, oxidative stress and Pulmonary function in patients with traumatic hemorrhagic shock (HS)."( Effects of Alprostadil Combined with Edaravone on Inflammation, Oxidative Stress and Pulmonary Function in Patients with Traumatic Hemorrhagic Shock.
Bao, W; Luo, D; Pan, Q; Wang, L; Zhao, W, 2022
)
1.38

Bioavailability

ExcerptReferenceRelevance
" We examined the hypothesis that the orally bioavailable PGE analogue enisoprost (EP) would improve renal function in renal transplant recipients chronically exposed to CYA."( A trial of the prostaglandin E1 analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction.
Cole, M; Hyndman, V; Knight, R; Lewis, R; Maddux, M; Mozes, MF; Pollak, R; Scott, E; Van Buren, C; Veremis, S, 1992
)
0.28
" bioavailability in unoperated fasted dogs."( SC-46275: a potent, long-acting gastric antisecretory prostaglandin with low oral bioavailability in the dog.
Bauer, RF; Burton, EG; Casler, JJ; Collins, PW; Gaginella, TS; Gasiecki, AF; Jones, PH; Perkins, WE; Tsai, BS, 1991
)
0.28
" It is concluded that new prostaglandin E1 analogues with oral bioavailability may have important applications to clinical transplantation in man, and may be cyclosporin sparing."( Immunosuppressive effect of misoprostol: a new synthetic prostaglandin E1 analogue.
Dumble, L; Moran, M; Pollak, R; Wiederkehr, JC, 1990
)
0.28
" We studied the immunosuppressive properties of new, synthetic, prostaglandin E1 (PGE1) methyl ester analogs (misoprostol, enisoprost) with oral bioavailability using an allogeneic in vitro immunoassay."( The immunosuppressive properties of new oral prostaglandin E1 analogs.
Dumble, LJ; Maddux, MS; Moran, M; Pollak, R; Wiederkehr, JC, 1990
)
0.28
"05), without significant changes in the rate of absorption (tmax = 14 +/- 8 [fasting] vs."( Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog.
Karim, A; Kowalski, KG; Rozek, LF; Smith, ME, 1989
)
0.28
" It is poorly absorbed after oral administration, and its metabolism occurs primarily in the stomach and jejunum."( Lubiprostone: chloride channel activator for chronic constipation.
Chagan, L; Rivkin, A, 2006
)
0.33
" Thus, the order of magnitude of absorption rate of the drug was as follows: nasal approximately = im > ip > sublingual."( Pharmacodynamic comparison of prostaglandin E1 administered by different routes to rats.
Cui, FD; Gao, YL; Gu, FG, 2007
)
0.34
" Lubiprostone has very low systemic bioavailability and cannot be quantitated in blood, but its active metabolite, M3, has been pharmacokinetically profiled."( Lubiprostone--a novel treatment for irritable bowel syndrome with constipation.
Owen, RT, 2008
)
0.35
" Secretory agents have high specificity, low bioavailability and high efficacy."( Review article: new receptor targets for medical therapy in irritable bowel syndrome.
Camilleri, M, 2010
)
0.36
" Vitaros©/Virirec© has a favorable pharmacodynamic profile and is poorly absorbed in systemic circulation."( Clinical efficacy and safety of Vitaros©/Virirec© (Alprostadil cream) for the treatment of erectile dysfunction.
Cuzin, B; Moncada, I,
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Our objective was to evaluate the bioequivalence, pharmacokinetics (PK), and bioavailability of lubiprostone sprinkles vs lubiprostone capsules, compared with placebo."( Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.
Adams, A; Barish, C; Chen, A; Dennis, P; Krause, R; Lichtlen, P; Losch-Beridon, T; Mareya, S; Schneider, J, 2021
)
0.62
"A 1-week randomized, placebo-controlled, double-blinded, bioequivalence study (study 302) and a single-dose PK and bioavailability crossover study (study 304) were conducted."( Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation.
Adams, A; Barish, C; Chen, A; Dennis, P; Krause, R; Lichtlen, P; Losch-Beridon, T; Mareya, S; Schneider, J, 2021
)
0.62

Dosage Studied

Twenty patients were enrolled in the study; two patients were excluded for poor penile turgidity. Of 278 (83%) men who entered the home phase, 277 men (247 with type II diabetes and 30 with type I diabetes) had evaluable data for alprostadil dosage and clinical response.

ExcerptRelevanceReference
" The average effective dosage of papaverine and PGE1 was variable among the different groups."( Intracavernous self-injection therapy for the treatment of erectile dysfunction.
Chiang, HS; Chiang, WH; Wen, TC; Wu, CC, 1992
)
0.28
" This was seen as a 5-6-fold right shift in the dose-response curves for AVP action (cAMP accumulation in intact cells and AC stimulation in homogenates and isolated membranes) and in a decrease in the maximum effect of AVP on these parameters."( Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization.
Antaramian, A; Birnbaumer, M; Gilbert, S; Themmen, AP, 1992
)
0.28
" After constructing a dose-response curve to either the beta-agonist isoproterenol or to PGE1 in a phenylephrine preconstricted vein, isoproterenol (271 ng/min), PGE1 (956 pg/min), or saline was infused for 4 h in separate experiments."( Desensitization of beta-adrenoceptor- and prostaglandin E1 receptor-mediated human vascular smooth muscle relaxation.
Blaschke, TF; Hoffman, BB; Vincent, J, 1992
)
0.28
" In the absence of other secretagogues, VIP produced a modest, sustained saliva flow with a biphasic dose-response curve in which saliva volume was greatest at 1 nM VIP (28."( Regulation of secretion by vasoactive intestinal peptide in isolated perfused rat submandibular glands.
Camden, JM; Turner, JT, 1992
)
0.28
" CYA dosing was fixed at existing levels."( A trial of the prostaglandin E1 analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction.
Cole, M; Hyndman, V; Knight, R; Lewis, R; Maddux, M; Mozes, MF; Pollak, R; Scott, E; Van Buren, C; Veremis, S, 1992
)
0.28
" We observed that PA and LPA not only stimulated the growth of MDCK cells (at 20 microM), but also stimulated the growth of normal rabbit kidney cells in serum free medium (albeit at a lower dosage of 5 microM)."( Phospholipids regulate growth and function of MDCK cells in hormonally defined serum free medium.
Bashir, N; Kuhen, K; Taub, M,
)
0.13
" The dosage was 28 to 64 ng/kg/min and was tapered down from 14."( Prostaglandin E1 reduces the frequency of rejection after heart transplantation.
Auer, T; Berger, J; Giegerl, E; Iberer, F; Kleinert, R; Popper, HH; Rehak, P; Tscheliessnigg, K; Vujicic, R; Wasler, A,
)
0.13
" E1-PG dosage varied from 10 to 40 mcg based on diagnosis, and was readjusted in 6 of the 9 patients which in the initial tests had not obtained sufficient erection, therefore bringing about a final 91."( [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
Alvarez González, E; Chandeck Montesa, K; Chen Jiménez, J; Rodríguez Antolín, A; Tamayo, JC, 1992
)
0.28
" After transcutaneous (16 cases), or intraoperative (90 cases) introduction of the catheter into superficial of profunda femoral artery, a continuous intraarterial administration of prostaglandin E1 was carried out in a dose of 10 nanograms/kg body weight/minute (total dosage 3000 nanograms)."( [Intra-arterial administration of prostaglandin E1 in occlusive arterial diseases].
Cernak, I; Davidović, L; Kostić, D; Lotina, S; Lovrić, A; Sagić, D; Vranes, M,
)
0.13
" The dose-response relations of carbachol-induced cAMP synthesis and carbachol-induced rise in intracellular free Ca2+ were similar."( Muscarinic receptor-linked elevation of cAMP in SH-SY5Y neuroblastoma cells is mediated by Ca2+ and protein kinase C.
Akerman, KE; Jansson, CC; Kukkonen, J, 1991
)
0.28
"Arachidonic acid (AA)- or thromboxane A2/prostaglandin H2 (TXA2/PGH2) analog (STA2 and U-46619)-induced aggregations yielded a bell-shaped dose-response curve."( Elevation of platelet cyclic AMP level by thromboxane A2/prostaglandin H2 receptor agonists.
Ishikawa, Y; Ogawa, A, 1991
)
0.28
" Prostaglandins E1 or E2, vasoactive intestinal peptide, carbachol, phenylephrine, or platelet-activating factor did not affect either the maximal cAMP response or the isoproterenol dose-response relationship."( Beta-adrenergic receptors on human tracheal epithelial cells in primary culture.
Davis, PB; Infeld, M; Kercsmar, CM; Silski, CL, 1990
)
0.28
" Further studies on dosage and treatment protocols would be justified."( The efficacy of oral Mifepristone (RU 38,486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability.
Ferguson, J; Hill, NC; MacKenzie, IZ, 1990
)
0.28
" Upon pretreatment with morphine over greater than or equal to 12 h, a fourfold shift of the PGE1-morphine dose-response curve was observed, whether or not IBMX was added."( Regulation of cyclic AMP by the mu-opioid receptor in human neuroblastoma SH-SY5Y cells.
Duan, DS; Eiger, S; Lameh, J; Sadée, W; Yu, VC, 1990
)
0.28
" The dose-response curves for priming were identical to those for triggering of an increase in [Ca2+]i and pHi."( Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors.
Kasahara, T; Kitagawa, S; Matsushima, K; Saito, M; Takaku, F; Yuo, A, 1991
)
0.28
" Thus the analysis revealed a positive risk benefit relation for PGE1, provided that dosage and contra-indications are not neglected."( [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
Heidrich, H, 1991
)
0.28
" Dose-dependent response with reversed drug sensitivity was found in the papaverine group, but only elongation to tumescence was found in the PGE1 group, even with double dosage (probably because of scarce PGE1 receptors in monkey's penile tissue)."( Histopathological change of corpora cavernosa after long-term intracavernous injection.
Chu, HW; Ho, WL; Hwang, TI; Yang, CR, 1991
)
0.28
" However, the dose-response curves were markedly shifted to the right in the cells from diabetic rats."( Evidence for impaired coupling of receptors to Gi protein in adipocytes from streptozocin-induced diabetic rats.
Green, A; Johnson, JL, 1991
)
0.28
" The addition of synthetic prostaglandins to the antiinflammatory glucocorticoid dosage regimen may prove to be of major therapeutic importance in the treatment of arthritic diseases by potentiating the effects of glucocorticoid on the reduction of the catabolism of articular cartilage."( Modulation of glucocorticoid receptor expression in human articular chondrocytes by cAMP and prostaglandins.
Cloutier, JM; DiBattista, JA; Martel-Pelletier, J; Pelletier, JP, 1991
)
0.28
" The fever dose threshold for the OVLT region was one-fifth those of the PO-AH area and the 3V, and the slope of the OVLT dose-response curve was twice those of the PO-AH and the 3V dose-response curves."( Differential sensitivity in the sites of fever production by prostaglandin E1 within the hypothalamus of the rat.
Stitt, JT, 1991
)
0.28
" RPF was not consistently altered by subacute/chronic dosing of indomethacin, misoprostol, or the combination of the drugs."( Minimization of indomethacin-induced reduction in renal function by misoprostol.
Brown, JA; Hall, PS; Klassen, DK; Schubert, C; Stromatt, SC; Voss, TE; Weir, MR, 1991
)
0.28
" Omeprazole, which suppresses acid very effectively, may be problematic in the critically ill, limited by its oral dosage form, acid-labile properties, and potential drug interactions."( Controlling gastric pH: the impact of newer agents on the critically ill patient.
Earnest, DL, 1990
)
0.28
" In an attempt to obtain data under basal conditions for pharmacological studies, we tested the dose-response effect of PGE1 on jejunal hydroelectrolytic movements in 10 healthy volunteers."( Human jejunal secretion induced by prostaglandin E1: a dose-response study.
Huchet, B; Rambaud, JC; Sobhani, I; Vidon, N, 1991
)
0.28
"The dose-response effects of 6-h intravenous infusion of PGI2 (0, 5, 10, 25 or 75 ng/kg/min) or PGE1 (0, 25, 50, 100 or 300 ng/kg/min) on skin hemodynamics and viability were studied in 4 x 10 cm random pattern skin flaps (n = 24) raised on both flanks of the pig."( Efficacy of intravenous infusion of prostacyclin (PGI2) or prostaglandin E1 (PGE1) in augmentation of skin flap blood flow and viability in the pig.
Forrest, CR; Kreidstein, ML; Pang, CY; Zhong, AG, 1991
)
0.28
" In vitro misoprostol demonstrated significant dose-response inhibition of the mixed lymphocyte culture assay."( Immunosuppressive effect of misoprostol: a new synthetic prostaglandin E1 analogue.
Dumble, L; Moran, M; Pollak, R; Wiederkehr, JC, 1990
)
0.28
" In a dosage of 800 micrograms daily in two or four divided doses, misoprostol produced rates of complete ulcer healing in both gastric and duodenal ulcer patients significantly superior to placebo and comparable to H2 receptor antagonists."( Misoprostol: discovery, development, and clinical applications.
Collins, PW,
)
0.13
"Four consecutive patients with alcoholic cirrhosis and hepatorenal syndrome were treated with misoprostol, a synthetic methylester prostaglandin E1 analogue at twice the dosage advocated for anti-ulcer therapy (i."( Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration.
De Groote, J; Fevery, J; Nevens, F; Van Cutsem, E; Van Steenbergen, W; Verberckmoes, R, 1990
)
0.28
" The inhibitory effect of cilostazol on platelet aggregation was potentiated by the presence of endothelial cells, and the slope of the dose-response curves were identified to be as the same between both experiments in the presence and the absence of endothelial cells."( Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.
Chijiwa, T; Igawa, T; Kato, S; Kawamura, K; Kimura, Y; Shimidzu, S; Shiragiku, T; Tani, T; Unemi, F, 1990
)
0.28
" The investigations aimed at collecting additional data contributing to the elaboration of optimal administration of the drug, its dosage and objective assessment of the obtained results."( [Results of the treatment of peripheral arterial diseases with PGE1].
Borkowski, M; Górewicz, R; Królicki, L; Kruk, M; Laszuk, D; Malmurowicz, L; Wojtal, E,
)
0.13
" Dose-response studies revealed that PGF2 alpha increased the potency of insulin in granulosa cells (EC50 for insulin-stimulation of oxytocin release reduced from 141 to 13 nmol/l by 1 mumol PGF2 alpha/l), but not in luteal cells."( Chronic regulation of ovarian oxytocin and progesterone release by prostaglandins: opposite effects in bovine granulosa and early luteal cells.
McArdle, CA, 1990
)
0.28
" To evaluate potential inhibitory actions, vessels were contracted by continuous LAD infusion of prostaglandin F2 alpha (PGF2 alpha) or serotonin before dose-response testing with PGE1 or nitroglycerin."( Prostaglandin E1 and nitroglycerin effects on canine epicardial conductance and distal coronary resistance vessels.
Bove, AA; Miller, WL, 1989
)
0.28
" The two vasodilators were infused in ten patients with mild or moderate ARDS at a dosage rate achieving a 20% reduction of the mean arterial pressure."( Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome.
Becker, H; Falke, KJ; Radermacher, P; Santak, B, 1989
)
0.28
"We studied the dose-response of focal gastric mucosal blood flow measured simultaneously by laser-Doppler flowmetry and hydrogen gas clearance in the canine chambered gastric segment to topical misoprostol (0."( The dose-response of canine focal gastric mucosal blood flow to misoprostol.
Gana, TJ; Koo, J; MacPherson, BR, 1989
)
0.28
" A possible dose-response relationship between PGE1 and its erectile action was examined in a double-blind, cross-over designed, placebo-controlled study."( Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction.
Schramek, P; Waldhauser, M, 1989
)
0.28
" Using digitonin-permeabilized cells we showed that adenylate cyclase activity was stimulated by prostaglandin E1 with the same dose-response relationship as was cyclic AMP accumulation in intact cells, but the permeabilized cells showed no response to angiotensin II."( Angiotensin II potentiates prostaglandin stimulation of cyclic AMP levels in intact bovine adrenal medulla cells but not adenylate cyclase in permeabilized cells.
Boarder, MR; Marriott, DB; Plevin, R, 1988
)
0.27
" Aldosterone (10(-6) mol/l) did not affect the dose-response curve of PGE1."( Effect of glucocorticoid on prostaglandin E1 mediated cyclic AMP formation by vascular smooth muscle cells.
Kohno, M; Murakawa, K; Takeda, T; Yasunari, K; Yokokawa, K, 1988
)
0.27
" A dose-response effect for enisoprost was found for the mean nocturnal hydrogen ion activity and pH, as well as for maximum pH attained."( Twenty-four-hour intragastric measurements in twenty healthy subjects: effect of enisoprost, a novel and potent antisecretory and antipeptic synthetic E1 prostaglandin.
Brunet, K; Cook, DJ; Fisher, D; Kirdeikis, P; McCullough, HN; Pinchbeck, B; Simpson, I; Thomson, AB; Wildeman, RA; Zuk, L, 1988
)
0.27
" Interestingly, in the absence of 1-methyl-3-isobutylxanthine (or an adenosine blocker), or in the presence of 1-methyl-3-isobutylxanthine (2 mM) and forskolin (30 microM), prostaglandin E1 (1 nM-100 microM) exhibited biphasic dose-response kinetics."( Interaction between prostaglandin E1 and forskolin in modulation of cyclic AMP levels in rat epididymal adipocytes.
Fatemi, SH, 1985
)
0.27
" Incubation of cells with pertussis toxin, however, did not significantly alter the dose-response curve for carbamylcholine effects on cGMP."( Effects of pertussis toxin on cAMP and cGMP responses to carbamylcholine in N1E-115 neuroblastoma cells.
Bruni, P; Burns, DL; Hewlett, EL; Moss, J, 1985
)
0.27
" Dose-response data indicate progressive PGE1-induced suppression of O2-."( Pharmacologic modulation by prostaglandin E1 of superoxide anion production by human polymorphonuclear leukocytes.
Zimmerman, JJ, 1986
)
0.27
" The dose-response curves of PGE1 were nearly the same for each of these three processes."( Possible involvement of cyclic AMP and calcium ion in prostaglandin E1-induced elevation of c-myc mRNA levels in Swiss 3T3 fibroblasts.
Hamamori, Y; Takai, Y; Tsuda, T; Yamashita, T, 1986
)
0.27
" At this dosage prostaglandin E1 was most effective in inducing artificial penile erection (11 of 12 patients)."( Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
Schramek, P; Waldhauser, M, 1988
)
0.27
" Ulcer-healing trials using four times daily dosing appear to parallel the antisecretory dose-response curve up to a dose of 200 micrograms qid."( Overview of misoprostol clinical experience.
Herting, RL; Nissen, CH, 1986
)
0.27
" Inhibition by topical retinoic acid of ODC induction by TPA was partially overcome in a dose-response fashion by PGE."( The role of prostaglandin E1 in ornithine decarboxylase induction by tumor promoters.
Boutwell, RK; Cleaveland, JS; Ordman, AB; Simsiman, RC, 1986
)
0.27
"The effect of misoprostol, a PGE1 methyl analogue, on the pregnant human uterus was unknown at dosage levels normally used in the treatment of gastric and duodenal ulceration."( [Effect of the PGE1 methyl analog misoprostol on the pregnant uterus in the first trimester].
Basse, H; Kiesel, L; Rabe, T; Runnebaum, B; Thuro, H, 1987
)
0.27
" No accumulation of misoprostol acid occurs in plasma following a 400 microgram q12h dosing regimen of misoprostol."( Antiulcer prostaglandin misoprostol: single and multiple dose pharmacokinetic profile.
Karim, A, 1987
)
0.27
" Hyperostosis of the marrow cavity in the sternum and femur was found predominantly in female mice of the medium (1,600 mcg/kg/day) and high dosage (16,000 mcg/kg/day) groups."( Hyperostosis of the marrow cavity caused by misoprostol in CD-1 strain mice.
Dodd, DC; Port, CD, 1987
)
0.27
" The plasma concentrations of propranolol under these steady state dosing conditions increased when misoprostol was added to propranolol."( Potential drug interactions with misoprostol: effects on the pharmacokinetics of antipyrine and propranolol.
Bennett, PN; Fenn, GC; Notarianni, LJ, 1988
)
0.27
" The results of 12 double-blind, randomized, placebo- and cimetidine-controlled trials involving 4000 patients have been reviewed here and show that misoprostol, given in a dosage of 800 micrograms daily in two or four divided doses, is able to produce rates of complete ulcer healing and pain relief in both gastric and duodenal ulcer which are significantly superior to placebo therapy and comparable to those achieved with high or conventional doses of cimetidine."( The therapeutic efficacy of misoprostol in peptic ulcer disease.
Akbar, FA; Hopkins, A; Watkinson, G, 1988
)
0.27
" Pretreatment with 20% ethanol markedly inhibited the gross mucosal damage caused by 70% ethanol dosing but the inhibition in the reduction of mucus glycoprotein content was restricted to about 80% of the untreated controls."( Mucus glycoprotein and mucosal protection.
Hotta, K; Ishihara, K; Kuwata, H; Ohara, S; Ohkawa, H; Okabe, H, 1988
)
0.27
" A linear dose-response relationship over the entire 14-560 nM range was also demonstrated in cultures containing serum, between the concentration of PGE1 in each culture, and the number of megakaryocyte colonies/clot and megakaryocytes/clot."( The effects of prostaglandin E1 on megakaryocyte proliferation in vitro.
Cooper, GW; Hou, XP, 1988
)
0.27
" Inhibition of PAF by SRI 63-441 alone, at the dosage and schedule used in these experiments, did not significantly prolong xenograft survival or function."( Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response.
Banner, B; Chapchap, P; Esquivel, CO; Makowka, L; Mazzaferro, V; Miller, C; Pan, C; Podesta, L; Pressley, D; Todo, S, 1987
)
0.27
" The drug is administered to ARDS patients by continuous intravenous infusion at dosage rates of up to 30 ng/kg/min for 7 days."( Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome.
Andreadis, NA; Bone, RC; Cox, JW; Maunder, RJ; Pullen, RH; Ursprung, JJ; Vassar, MJ, 1988
)
0.27
" A lower dosage of prostaglandin E1 (1 ng/kg/min) infusion was effective in seven dogs, which prevented lung deterioration, and five of the seven lungs were well preserved for 10 hours with stable arterial oxygen tension, pulmonary vascular resistance, and pulmonary compliance."( Beneficial effects of prostaglandin E1 on autoperfused heart-lung preservation.
Bergsland, J; Bhayana, JN; Celik, CF; Lajos, TZ; Miyamoto, Y,
)
0.13
"5 microM), however, the slope of the dose-response curve for EtOH stimulation of AC activity was biphasic."( Effects of ethanol on adenylate cyclase system in the human platelet.
Ishizawa, H; Ozawa, H; Saito, T; Tabakoff, B; Tsuchiya, F, 1987
)
0.27
"Plasma and knee joint synovial fluid (SF) concentration of diclofenac sodium and its hydroxylated metabolites were measured after chronic dosing with the 100 mg polymer matrix formulation."( Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation.
Dawes, PT; Fowler, PD; John, VA; Shotton, PA, 1986
)
0.27
" As indicated by a dose-response study, 6-keto-PGE1 and PGE2 did not differ in their ability to bring about decidualization."( 6-Keto-prostaglandin E1 and the decidual cell reaction in rats.
Doktorcik, PE; Kennedy, TG, 1986
)
0.27
"Cumulative dose-response curves for histamine induced responses in mesometrial (ME) and antimesometrial (AME) regions of uterine horns isolated from rats at 7th, 16th and 22nd days of pregnancy, were constructed."( Is there a prostaglandin involvement in the positive inotropic action of histamine in isolated pregnant rat uterus, apparently mediated via H1-receptors activation?
Dveksler, G; Franchi, AM; Gimeno, AL; Gimeno, MF; Viggiano, M, 1987
)
0.27
" Three-point dose-response curves were initially determined for all women."( The effect of prostaglandin E1 upon the pressor and hormonal response to exogenous angiotensin II in human pregnancy.
Broughton Pipkin, F; Morrison, R; O'Brien, PM, 1987
)
0.27
" Fifteen micrograms of OP1206 was given initially, and the dosage was increased to 30 micrograms whenever there were no adverse effects."( Oral prostaglandin E1 as a therapeutic modality for leg ulcers in Behçet's disease.
Hashimoto, T; Takeuchi, A, 1987
)
0.27
" Based on a therapeutic index obtained from the ratio of clinical dosage to IC90, the derivatives proved to be of value in further in vivo studies."( [Cell-killing effect in vitro of prostaglandin derivatives on an established human bladder cancer cell line, KK-47].
Hisazumi, H; Uchibayashi, T, 1985
)
0.27
" Optimal activity was observed 30-60 min after dosing and activity was sustained throughout the experimental period."( Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
Cleland, ME; McCraw, AP; Nishio, S; Sim, AK; Umetsu, T, 1985
)
0.27
" This problem has been solved by pharmaceutical formulation studies which led to a stable and solid dosage form."( Chemistry and synthetic development of misoprostol.
Collins, PW; Dajani, EZ; Pappo, R, 1985
)
0.27
" In the single dosage range of 50-200 micrograms, misoprostol inhibits gastric acid secretion in a dose-related manner both in the basal state and after stimuli such as histamine and standard test meals."( Misoprostol clinical pharmacology. Establishment of activity in man.
Steiner, JA, 1985
)
0.27
" Dose-response curves were constructed for five agents."( The effectiveness of local injections of vasodilating agents to produce vasodilation in subcutaneous tissue in rabbits.
DeYoung, NJ; Duncan, HJ; Faris, IB, 1985
)
0.27
" However, the dose-response curve for the GppNHp-dependent increase in [3H]forskolin binding sites is shifted to lower concentrations in the presence of prostaglandin E1."( Regulation of [3H]forskolin binding to human platelet membranes by GppNHp, NaF, and prostaglandin E1.
Nelson, CA; Seamon, KB, 1985
)
0.27
"Increasing doses of prostaglandin E1 given intravenously do not influence the hemodynamic parameters up to a dosage of 1500 ng/min."( Circulation parameters during intravenous and intra-arterial administration of increasing doses of prostaglandin E1 in healthy subjects.
Ayaz, M; Brecht, T, 1985
)
0.27
" The time course of inhibition, the extent of inhibition, and the dose-response relationship did not differ between the groups."( Normal alpha 2-adrenergic responses in platelets from patients with asthma.
Davis, PB; Lieberman, P, 1982
)
0.26
" Water consumption was increased both during and after the dosing period for the mid and high dose dams."( Two-phase teratology study with the synthetic prostaglandin ONO-802 given intravaginally to rats.
de la Iglesia, FA; Fitzgerald, JE; Humphrey, RR; Petrere, JA; Sakowski, R, 1984
)
0.27
" Inhibition of aggregation by the beta-adrenoceptor antagonists was manifested as a parallel shift to the right in the dose-response curve."( Beta-adrenoceptor antagonists and human platelets: relationship of effects to lipid solubility.
Kerry, R; Scrutton, MC; Wallis, RB, 1984
)
0.27
" Dose-response curves and kinetics of inhibition were identical to those obtained in cultures stimulated by combinations of growth factors that do not increase the intracellular level of cAMP."( Cyclic AMP does not mediate inhibition of DNA synthesis by interferon in mouse Swiss 3T3 cells.
Ebsworth, NM; Rozengurt, E; Taylor-Papadimitriou, J, 1984
)
0.27
" Each treated rat received 10 micrograms/kg PGE1 in the initial bolus and a maintenance dosage of 10 micrograms/kg/h via the infusate."( Prostaglandin E1 treatment in experimental acute pancreatitis in the rat.
Brackett, K; Crocket, A; Crocket, KV; Jacobson, ED; Joffe, SN; Rao, SS, 1984
)
0.27
" As measured by magnitude of inhibition and dose-response titration, ADCC activity is less sensitive to the effects of PGE1 than is NK activity in the 51Cr release assay and single-cell assay."( Natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) activities can be differentiated by their different sensitivities to interferon and prostaglandin E1.
Merrill, JE, 1983
)
0.27
" The response of progeria cells to a hormone preparation with insulin-like activity was decreased, while in normal cells this decrease occurred as a function of passage level with a "shift to the right" of the dose-response curve."( Some aspects of cellular aging.
Goldstein, S; Harley, CB; Moerman, EJ, 1983
)
0.27
"These studies were designed to determine the dose-response autonomic and behavioral thermoregulatory effects and the motor effects of dopamine (DA) and prostaglandin E1 (PGE1) injected into the lateral cerebral ventricles of rats."( Behavioral thermoregulation, core temperature, and motor activity: simultaneous quantitative assessment in rats after dopamine and prostaglandin E1.
Burks, TF; Marques, PR; McDougal, JN; Spencer, RL, 1984
)
0.27
" More detailed dose-response studies revealed that the I50 for inhibition of PG production by dexamethasone was less than 10 nM, thus indicating that the steroid effect probably involved high affinity glucocorticoid receptors."( Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone.
Mitchell, MD; Polansky, JR; Weinreb, RN, 1983
)
0.27
" Moreover, in vitro cumulative dose-response curves for the contractile effect of these three PGs, on identical oviductal segments, were constructed."( Role of endogenous and exogenous prostaglandins on the contractile functioning of isolated sow (Sus scrofa) oviducts.
Chaud, M; Franchi, AM; Gimeno, AL; Gimeno, MF; Gonzalez, ET; Viggiano, M, 1984
)
0.27
" The reduction in gastric bleeding with the 50-microgram dosage of misoprostol was directly related to the reduction in acid secretion."( Effect of synthetic prostaglandin E1 analog on aspirin-induced gastric bleeding and secretion.
Hunt, JN; Jiang, CL; Kessler, L; Smith, JL, 1983
)
0.27
" The dose-response curves of the adenylate cyclase activity measured as a function of the beta 2-glycoprotein I concentration were S-shaped in the absence of prostaglandin E1 and hyperbolic in its presence."( Effect of beta 2-glycoprotein I on the activity of adenylate cyclase in platelet membranes.
Schousboe, I, 1983
)
0.27
" Dose-response contractile activity to PGs with and without gassing was explored."( Does hypoxia selectively stimulate the generation of prostaglandin E1 by the isolated rat uterus?
Borda, ES; Chaud, M; Gimeno, AL; Gimeno, MF; Lazzari, M, 1981
)
0.26
" Animals then received Prostaglandin E1 (PGE1), Tolazoline (TOL), and Prostacyclin (PGI2) in varying dosages until PVR was reduced or the dosage no longer tolerated."( Comparative studies on the hemodynamic effects of prostaglandin E1 prostacyclin, and tolazoline upon elevated pulmonary vascular resistance in neonatal swine.
Elliott, RB; Elliott, RL; Neutze, JM; Starling, MB, 1981
)
0.26
" Seven sheep alternately received Escherichia coli endotoxin and endotoxin plus PGE at a dosage of 1 microgram/kg/min."( Prostaglandin infusion and endotoxin-induced lung injury.
Demling, RH; Gunther, R; Smith, ME; Zaiss, C, 1982
)
0.26
" Parallel log dose-response relationship were seen for decreases in blood pressure and increases in mesenteric blood flow with both prostaglandins when infused into the aortic arch."( Comparison of the pulmonary, hepatic and renal extraction of PGI2 and 6-keto-PGE1.
Branch, RA; Gerkens, JF; Jackson, EK; Tsunoda, S, 1982
)
0.26
" The dose-response curve of VIP in the presence of PGE1 was shifted to the left and the maximal effect of VIP was significantly enhanced."( VIP and PGE1 activate adenylate cyclase in rat intestinal epithelial cell membranes via different mechanisms.
Beubler, E, 1981
)
0.26
" Postoperative A-a DO2 and respiratory index (RI) as functional parameters of oxygenation capacity, dosage of dopamine were monitored at 0, 3, 6, 12, 18 and 24 hr after termination of CPB and at extubation period."( [Effects of combined aprotinin and prostagrandin E1 therapy on aortic arch replacement].
Abe, H; Abe, K; Gotoh, S; Iijima, Y; Inui, K; Kuraoka, S; Murai, K; Orita, H; Uchino, H; Watanabe, T, 1995
)
0.29
" Exposure of transfected cells to human chorionic gonadotropin (hCG) resulted in a dose-dependent loss of maximal hCG-stimulable adenylyl cyclase activity without a significant shift to the right of the dose-response curve to hCG."( Homologous desensitization of the murine luteinizing hormone receptor expressed in L cells.
Birnbaumer, L; Birnbaumer, M; Gudermann, T, 1995
)
0.29
" Utilizing the dorsal hand vein technique, dose-response curves to bradykinin (maximum dose = 513 ng/min) were constructed in veins preconstricted with the alpha-adrenergic agonist phenylephrine in healthy young volunteers."( Mechanism of bradykinin-induced venodilation in humans.
Blaschke, TF; Dachman, WD; Ford, GA; Hoffman, BB, 1993
)
0.29
" The authors studied whether skin surface oxygen pressure histograms change depending on dosage and route of administration of prostaglandin E1 (PGE1), whether they are of predictive value for patients' clinical outcome, and whether they normalize after therapy with PGE1."( Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.
Alexander, K; Arnold, A; Caspary, L; Creutzig, A; Thum, J, 1995
)
0.29
" Thus, this dosage form is expected to be highly effective for a drug delivery of PGE1 in clinical treatment."( Rate of release and retentivity of prostaglandin E1 in lipid emulsion.
Fukushima, Y; Hayashi, H; Itai, S; Yamaguchi, T, 1995
)
0.29
"2 office sessions were required to learn adequate self-injection technique and determine optimal dosage requirement."( Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction.
Bagley, DH; Carsello, J; Chancellor, MB; Hirsch, IH; Smith, RL; Staas, WE, 1994
)
0.29
" PGE1 always achieved the best response, SIN-1 performed statistically significantly poorer irrespective of the dosage used."( Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction.
Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1994
)
0.29
" Dose-response curves for sodium nitroprusside, nitroglycerin, isoproterenol, amrinone, and PGE1 were then generated."( Pulmonary vascular smooth muscle relaxation by cGMP- versus cAMP-mediated mechanisms.
Banerjee, A; Fullerton, DA; Hahn, AR; Harken, AH, 1994
)
0.29
" The dosage of postoperative analgesic was significantly less in these patients."( [Anesthesia for modified radical mastectomy with breast reconstruction].
Higuchi, A; Iwaki, K; Kamitani, K; Kubo, H; Shimizu, Y, 1994
)
0.29
" The mean PGE1 dosage injected was 6 micrograms and mean duration of erection preceding aspiration 180 minutes."( Pharmacologic erection: time-dependent changes in the corporal environment.
Broderick, GA; Harkaway, R, 1994
)
0.29
"The effects of different dosage of PGE1 on hemodynamics, oxygen delivery (DO2), oxygen consumption (VO2) and hemorheology in patients with pulmonary arterial hypertension (PAH) were investigated."( [Effects of different dosage of PGE1 in pulmonary arterial hypertension].
Guo, ZH; Jing, BW; Ye, YQ, 1993
)
0.29
" Techniques of injection, dosing and followup are discussed."( Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
Chao, R; Clowers, DE, 1994
)
0.29
"We report a double-blind, randomized, placebo-controlled, dose-response study of prostaglandin E1 as treatment for erectile failure."( Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study.
Chen, J; Godschalk, MF; Katz, PG; Mulligan, T, 1994
)
0.29
" Summary parameters to characterize erection with each dosage were developed: maximal rigidity, maximal rigidity sustained for 30 minutes and duration of greater than 60% rigidity."( A prostaglandin E1 dose-response study in man.
Brock, GB; Donatucci, CF; Lue, TF; Marshall, GA; von Heyden, B, 1993
)
0.29
" After surgery Lipo-PGE1 was used at a dosage of 5 ng/kg per minute from days 2-9 during which aneurysmal dilatation (7 mm in diameter) developed and remained thereafter."( Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.
Aonuma, K; Baba, A; Komiyama, A; Tohyama, M; Tsuno, T, 1993
)
0.29
" The comparative dose-response relationships from PGE1 given by osmotic minipump or controlled-release pellet on periosteal and intracortical bone envelopes were determined."( Local stimulation of new bone formation by prostaglandin E1: quantitative histomorphometry and comparison of delivery by minipumps and controlled-release pellets.
Marks, SC; Miller, SC,
)
0.13
" After right heart catheterization in patients with more than 3 Wood units or with a mean pulmonary artery pressure higher than 30 mm Hg (n = 13; group 1), prostaglandin E1 (PGE1) therapy was initiated at a dosage of 5 ng/kg/min and was increased stepwise (mean maintenance dosage, 35 ng/kg/min) until side effects (joint pain, digital edema) occurred."( Prostaglandin E1-induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation.
Auer, T; Iberer, F; Müller, H; Petutschnigg, B; Rödl, S; Tscheliessnigg, K; Wasler, A,
)
0.13
" We describe the procedure to establish the dosage for home use and discuss the implications of the low dosages relative to previous reports."( Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
Donatucci, CF; Kaula, N; Lue, TF; von Heyden, B, 1993
)
0.29
" The dose-response curve for melatonin shows an approximate 1000-fold shift in potency in the RCS rat."( Agonist-induced effects on cyclic AMP metabolism are affected in pigment epithelial cells of the Royal College of Surgeons rat.
Nash, MS; Osborne, NN, 1995
)
0.29
" The model applied for the analysis may be thought to be the best means presently to relate dose-response dependencies to what is known or can be hypothesized about the mechanisms underlying inhibition of AC activity."( Analysis of effects of adrenaline and collagen on the activity of prostaglandin E1-stimulated human platelet adenylyl cyclase.
Juska, A, 1996
)
0.29
" A dose-response relation was observed during the double-blind phase; the 10-micrograms dose was effective in 55."( Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction.
Calabrò, A; Colli, E; Gentile, V; Mirone, V; Soli, M, 1996
)
1.74
"Pharmacists need to be aware of the potentially serious skeletal changes, encourage dosage titration as soon as possible, and limit the duration of time neonates are exposed to prostaglandin therapy."( Bone and tissue changes following prostaglandin therapy in neonates.
El-Chaar, GM; Kaufman, MB, 1996
)
0.29
"To test the hypothesis that unbound concentrations of naproxen in synovial fluid (SF) and plasma (P) are equal over a drug dosage interval at steady state or after a single dose of drug."( Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.
Day, RO; Francis, H; Geisslinger, G; Vial, J; Williams, KM, 1995
)
0.29
" The dose-response characteristics of two nitrovasodilators, sodium nitroprusside and nitroglycerin, and two nonnitrovasodilators, prostaglandin E2 and 5'-N-ethylcarboxamidoadenosine, were studied."( Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension.
Kavanagh, BP; Pearl, RG; Thompson, JS, 1996
)
0.29
" In contrast, pretreatment with L-NAME resulted in no changes in the dose-response characteristics of the cyclic adenosine monophosphate-mediated, NO-independent vasodilators prostaglandin E1 and 5'-N-ethylcarboxamidoadenosine."( Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension.
Kavanagh, BP; Pearl, RG; Thompson, JS, 1996
)
0.29
" They received testing dosage starting from 5 micrograms with increasing dosage (maximum 20 micrograms) to achieve a rigid erection of Schramek's grade 5 and lasting for at least 20 min."( Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
Chu, NK; Tang, SF; Wong, MK, 1995
)
0.29
" It is suggested that a suitable dosage of fentanyl is effective without causing serious side effects for neonate."( [Anesthesia for a patient with HELLP syndrome].
Sakio, H; Satoh, T; Takahashi, H, 1996
)
0.29
" Seven patients received an infusion of PGE1 (Prostavasin) at a dosage of 60 micrograms over 2 hours, while in 6 patients (control group) isotonic saline was given as placebo."( [Effect of prostaglandin E1 on extravascular lung water in patients with severe heart failure].
Buder, R; Kramer, L; Kranz, A; Lenz, K; Schollmayer, E, 1996
)
0.29
" The central neurogenic group was the most responsive to PGE-1 therapy, requiring an average maintenance dosage of 5 mcg."( Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy.
Abbott, L; Hirsch, IH; Ismail, M, 1997
)
0.3
"Eighty patients with stenosis or occlusion, symptoms of intermittent claudication, and maximum walking distance of > or = 30 and < or = 300 m on a standard treadmill test were randomized to placebo or one of three dosage regimens of AS-013."( Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication.
Belch, JJ; Bell, PR; Creissen, D; Dormandy, JA; Kester, RC; McCollum, RD; Mizushima, Y; Ruckley, CV; Scurr, JH; Wolfe, JH, 1997
)
0.3
" Studies to investigate the optimal dosing regimen, duration of clinical benefit, and effects in more severe forms of peripheral arterial disease are warranted."( Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication.
Belch, JJ; Bell, PR; Creissen, D; Dormandy, JA; Kester, RC; McCollum, RD; Mizushima, Y; Ruckley, CV; Scurr, JH; Wolfe, JH, 1997
)
0.3
" Both PIA and PGE1 (which downregulate Gi) decreased the maximal responsiveness of the cells to insulin by approximately 30% and caused a rightward shift in the dose-response curve."( Insulin resistance in adipocytes after downregulation of Gi subtypes.
Belt, SE; Green, A; Walters, DJ, 1997
)
0.3
" In parallel experiments, cycling naive vascular SMC isolated from nonpurified diet-fed mice were dosed with exogenous prostaglandin E1 (PGE1 ) for various periods and challenged with cycloheximide for 4 h (8-12 h after PGE1 addition), and intracellular cAMP levels were measured at various time points."( Dietary gamma-linolenic acid enhances mouse macrophage-derived prostaglandin E1 which inhibits vascular smooth muscle cell proliferation.
Chapkin, RS; Fan, YY; Ramos, KS, 1997
)
0.3
" Additional studies with larger sample sizes are recommended to determine the optimal misoprostol dosage and frequency of administration."( Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion.
Eng, NS; Guan, AC, 1997
)
0.3
"The stable thromboxane A2 mimetic, U46619, was infused in increasing dosage to obtain a stable pulmonary hypertension of approximately 30 mm Hg."( Efficacy of inhaled prostanoids in experimental pulmonary hypertension.
Habler, O; Hofstetter, C; Kleen, M; Mueller, M; Pusch, R; Welte, M; Zwissler, B, 1998
)
0.3
" Groups B (n=10) and C (n=10) received oxygenated blood at the same rate, with PGE1 at the dosage of 25 and 50 ng/kg/min, respectively."( Prevention of spinal cord ischemia by selective intercostal arterial infusion of prostaglandin E1.
Katada, S; Kawasuji, M; Ohtake, H; Tamura, M; Urayama, H; Watanabe, Y, 1998
)
0.3
" The reduced dosage was used only at the first cycle (week 0) to evaluate reduced tolerability or side effects."( Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
Agus, G; Barsotti, A; Belcaro, G; Bucci, M; Cazaubon, M; Cesarone, MR; Christopoulos, D; Cornelli, U; Corsi, M; DeSanctis, MT; Errichi, BM; Ferrari, PG; Geroulakos, G; Helmis, H; Iacobitti, P; Incandela, L; Ippolito, E; Laurora, G; Ledda, A; Mezzanotte, L; Nicolaides, AN; Pomante, P; Ramaswami, G; Ricci, A; Vasdekis, S, 1998
)
0.3
" Using blood pressure measurements, especially systolic BP and MABP as measured in a flat supine position, the dosage of alprostadil required to achieve satisfactory erections in men with organic impotence can be predicted."( Factors in predicting initial in-office therapeutic dosages of alprostadil for the treatment of organic impotence.
Intili, H, 1998
)
0.75
" Those with a starting dosage of 10-20 micrograms, those with psychogenic causes of dysfunction, and those with no prior treatment for erectile dysfunction generally showed the greatest improvements."( Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa.
Erder, MH; Glick, HA; Linet, OI; Parkerson, GR; Willke, RJ; Yen, W, 1998
)
0.6
" A dosage of 200 micrograms qid is recommended for prophylaxis, for the duration of NSAID therapy."( P & T committee review of misoprostol: prevention of NSAID side effects is key--roundtable discussion.
Fries, J; Graham, D; Knodel, LC; Silverstein, F; Weintraub, M, 1989
)
0.28
" With the usual dosage approved in PAOD, no significant influence on cardiac performance was observed."( Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. The Alprostadil Investigators.
Bernink, PJ; Borer, JS; Caspi, A; Marmor, A; Rabinowitz, B; Reisin, L; Ruzyllo, W,
)
0.34
"In a placebo-controlled, double-blind study, we investigated the hemodynamic effects of a single infusion of prostaglandin E ( 1 ) (PGE ( 1 ); 60 microg infused over a period of 2 hours, the unit dosage used in courses of treatment for peripheral occlusive arterial disease) in 20 patients with moderate to severe chronic heart failure (New York Heart Association functional class II or III)."( Hemodynamic effects of a single intravenous infusion of prostaglandin E1 in patients with clinically moderate to severe chronic heart failure.
Bannaie, M; Dagres, N; Erbel, R; Fuchs, JB; Gschossmann, J; Meyer, J; Mohr-Kahaly, S; Rink, C; Schrader, N; Wittlich, N,
)
0.13
" Group I (12 patients) received only the conventional medications before and after protocol, and group II (18 patients) received intravenous PGE ( 1 ) infusion for 24 hours starting at least 2 hours before angiography after hemodynamically based titration to a mean dosage of 16 +/- 3 ng/kg/min (range, 10-20 ng/kg/min)."( Prostaglandin E1 during angioplasty as preventative therapy for coronary restenosis.
Agranat, O; Har-Zahav, Y; Kaplinsky, E; Rabinowitz, B; Rath, S; Shechter, M,
)
0.13
" PGE2 and misoprostol had bell-shaped dose-response curves: constriction by low doses of PGE2 and misoprostol (0."( Dilatation and constriction of rat gastric mucosal microvessels through prostaglandin EP2 and EP3 receptors.
Boku, K; Hayashi, H; Katori, M; Majima, M; Nishiyama, K; Ohno, T; Saeki, T; Saigenji, K, 1999
)
0.3
"Twelve females, aged 50-67 years, were included in the study with six of them receiving a 3-hour infusion of alprostadil at the standard dosage of 60 micrograms in 250 cc of physiological infusion for six consecutive days and the remaining six receiving placebo (250 cc of physiological infusion administered in the same manner)."( Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
Barbera, N; Bartolone, S; De Nuzzo, G; Larosa, D; Raffa, A; Scamardi, R; Sottilotta, G; Trifiletti, A, 1999
)
0.52
"Previous studies have shown that oral administration of 300 mg alpha-tocopherol/day to healthy volunteers decreases platelet function and enhances their sensitivity to the platelet inhibitor, prostaglandin E(1), when full dose-response curves to a range of agonist concentrations are made."( Moderate supplementation with natural alpha-tocopherol decreases platelet aggregation and low-density lipoprotein oxidation.
Bruckdorfer, KR; Mabile, L; Rice-Evans, C, 1999
)
0.3
" Initial experience also indicates that PGE1 given at a dosage of 25 micrograms every three hours is more effective than intravenous oxytocin or local PGE2, but this advantage appears to be accompanied by an increase in the incidence of uterine hyperstimulation and associated fetal heart rate changes."( [Evidence-based medicine: labor induction with prostaglandins].
Rath, W; Winkler, M, 1999
)
0.3
"9 months, and the PGE1 dosage 13."( Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years.
Altinkilic, BM; Hauck, EW; Rudnick, J; Schroeder-Printzen, I; Weidner, W, 1999
)
0.3
" Between 150 and 250 injections during 3 years were performed, and the dosage varied from 5 to 20 microg."( Does prostaglandin E1 therapy modify the intracavernous musculature?
Noël, JC; Sattar, AA; Schulman, CC; Wespes, E, 2000
)
0.31
" The reduced dosage was used only at the first cycle to evaluate reduced tolerability or side effects."( [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
Belcaro, G; Bucci, M; Cesarone, MR; Corsi, M; Dugall, M; Laurora, G, 1998
)
0.3
" The mean dosage administered in most patients (83% were treated with the short-term protocol) had been 20 + 40 micrograms on the first day and 60 + 40 micrograms on the second day."( [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
Belcaro, G; Cesarone, MR; De Sanctis, MT; Dugall, M; Incandela, L; Laurora, G, 1998
)
0.3
" Therefore, PGE1 at the dosage used in this study did not increase bone formation but increased bone resorption in humans."( The effect of prostaglandin E1 on human bone metabolism: evaluation by biochemical markers for bone turnover.
Hoshino, H; Inoue, T; Ishihara, C; Kushida, K; Takahashi, M, 2000
)
0.31
" On successive visits, the patient injects himself and the dosage is titrated until a satisfactory erection is obtained."( A simplified pharmacologic erection program for patients with spinal cord injury.
Britanico, J; Galea, G; Nicolis, C; Vapnek, JM; Zaslau, S, 1999
)
0.3
" In the five patients of group B, lipo-PGE1 was replaced with a relatively high dosage of PGE1-CD (50-100 ng/kg per min), resulting in good ductal patency until surgery."( Echocardiographic evaluation of the ductal morphology in patients with refractoriness to lipo-prostaglandin E1 therapy.
Agata, Y; Fujino, N; Hiraishi, S; Hirota, H; Horiguchi, Y; Kawamura, S; Misawa, H; Ogawa, N; Takeda, N, 2000
)
0.31
") at a dosage of 300 or 450 mg/kg of body weight or subcutaneously (s."( Role of cytoprotectants and nitric oxide inhibition in nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in the rat.
Albassam, MA; Lillie, LE; Macallum, GE; Percy, DH; Turner, PV, 2000
)
0.31
" The most common reasons included lack of efficacy (n = 3, all in the home phase), intolerable penile pain (1 in the titration phase, 2 in the home phase) and dissatisfaction with the higher dosage (n = 2)."( Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction.
Lin, JS; Lin, YM; Tsai, YS, 2000
)
0.62
" This progressive method of treatment enabled us to select the optimal dosage and combinations of compounds in 441/452 patients (97."( [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Baniel, J; Israilov, S; Livne, P; Segenreich, E; Shmueli, J; Simon, D, 1998
)
0.3
" The reduced dosage was used only at the first cycle (week 0) to evaluate tolerability or side effects."( PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
Agus, G; Barsotti, A; Belcaro, G; Bucci, M; Cesarone, MR; Christopoulos, D; Cornelli, U; Corsi, M; De Angelis, R; De Sanctis, MT; Di Francescantonio, D; Dugall, M; Errichi, BM; Ferrari, PG; Geroulakos, G; Helmis, H; Incandela, L; Ippolito, E; Ledda, A; Martines, G; Mondani, P; Nicolaides, AN; Pellegrini, L; Ramaswami, G; Ricci, A; Vasdekis, S, 2000
)
0.31
" The circulatory and metabolic conditions under induced hypotensive anesthesia were influenced by both vasodilators and anesthetics, and the dosage of vasodilator to decrease arterial blood pressure was dependent on the anesthetic used simultaneously."( [Comparisons of vasodilators and anesthetics in their effects on the circulatory and metabolic conditions during hypotensive anesthesia].
Toi, T, 2000
)
0.31
" The most effective of the three PGE1 dosing regimens was 20 ng/kg/min."( Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study.
Bernink, PJ; Brinker, J; Koch, JA; Schollmayer, E; Sketch, MH; Whelton, A; Woltering, F,
)
0.13
" The injections were then repeated with increasing dosage to archive a rigid erection."( [Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients].
Boiteau, F; Boyer, F; Dizien, O; Laffont, I; Lebib Ben Achour, S, 2001
)
0.31
" Rigiscan was used for the objective determination of the initial dosage and then doses were regulated in order to introduce an erection suitable for penetration and maintenance of erection for 30 min."( Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs.
Athanasopoulos, A; Barbalias, G; Gyftopoulos, K; Perimenis, P, 2001
)
0.31
" Frequent follow-up visits and the adjustment of dosage to continue the success of therapy may prevent patient dissatisfaction and drop-out from treatment."( Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs.
Athanasopoulos, A; Barbalias, G; Gyftopoulos, K; Perimenis, P, 2001
)
0.31
"1 mg dosage in 150-200 ml isotonic solution of sodium chloride during 15 days."( [Clinical efficacy of alprostan in combination with "Bioptron-II" rays and iruxol-miramistin in the treatment of the diabetic foot complicated by atherosclerosis].
Tomashuk, II; Tomashuk, IP, 2001
)
0.31
" Of 278 (83%) men who entered the home phase, 277 men (247 with type II diabetes and 30 with type I diabetes) had evaluable data for alprostadil dosage and clinical response."( Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men.
Belanger, A; Benard, F; Brock, G; Casey, R; Guangwei, L; Heaton, JP; Israr, D; Kim, JJ; Kim, SC; Litonjua, AD; Liu, SN; Lording, D; Niazi, D; Rajatanavin, R; Suyono, S; Zhi-Zhou, S, 2001
)
0.86
"Forty cases of chronic pulmonary heart disease at the acute stage were treated with PGE1 at the dosage of 100 micrograms."( [Efficacy of prostaglandin E1 in the treatment of chronic pulmonary heart disease in the elderly people at the acute stage].
Huang, CC; Xu, M, 2001
)
0.31
" These findings indicate that PRK modeling based on the intensities of the observed pharmacological response-time data is a meaningful tool in some targeting-type drugs, for which pharmacokinetic analysis itself is meaningless or acquisition of pharmacokinetic data is technically impossible, in predicting the time courses of the drug's pharmacological response in different dosage regimens."( An approach to predict the ductus-arteriosus dilating effect induced by lipo-prostaglandin E1 in newborn rats lacking plasma concentration-time data by the pharmacological response kinetic model.
Kawasaki, H; Kurosaki, Y; Yamauchi, K; Yasunaga, S, 2003
)
0.32
"To evaluate the efficacy of intrameatal application of low dosage alprostadil (PGE1) cream (300 mcg) for the treatment of erectile dysfunction (ED)."( [The therapeutic efficacy for ED patients treated with low dosage of PGE1].
Chen, YX; Liao, B; Lu, AH; Lu, MQ; Ou, RB; Wan, ST; Zhang, B; Zhao, D, 2003
)
0.56
" A dosage of 300 mg PGE1 in 75 mg cream was applied intrameatally."( [The therapeutic efficacy for ED patients treated with low dosage of PGE1].
Chen, YX; Liao, B; Lu, AH; Lu, MQ; Ou, RB; Wan, ST; Zhang, B; Zhao, D, 2003
)
0.32
"With intrameatal low dosage (300 mcg PGE1) of the PGE1 cream can achieve an equivalent efficacy as that with the full dosage."( [The therapeutic efficacy for ED patients treated with low dosage of PGE1].
Chen, YX; Liao, B; Lu, AH; Lu, MQ; Ou, RB; Wan, ST; Zhang, B; Zhao, D, 2003
)
0.32
"Chemotherapy of solid tumors is presently largely ineffective at dosage levels that are compatible with survival of the patient."( Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy.
Ahlström, H; Iversen, VV; Johansson, L; Koisti, M; Reed, RK; Rubin, K; Salnikov, AV; Sjöquist, M; Stuhr, LB; Sundberg, C, 2003
)
0.32
"2 years, mean dosage 35 ng/kg per min over 6-8 days)."( Preoperative prostaglandin E1 treatment to prevent right ventricular failure after orthotopic heart transplantation.
Auer, T; Berger, J; Gombotz, H; Iberer, F; Metzler, H; Petutschnigg, B; Tscheliessnigg, KH; Wasler, A, 1992
)
0.28
" A short regimen of gemeprost was used: over a 24-h period, 1 mg vaginal gemeprost was given every 3 h up to three doses after which, if abortion did not occur, another course at the same dosage schedule was administered up to 4 days."( A short-scheme protocol of gemeprost for midtrimester termination of pregnancy with uterine scar.
Pontrelli, G; Santamato, S; Scioscia, M; Selvaggi, L; Vimercati, A, 2005
)
0.33
" We set out to evaluate the impact of varying the ingredient dosage on response and short-term safety of Tx compared with PgE1."( A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
Akhras, AA; Mohamed, K; Rashwan, H; Seyam, R,
)
0.13
" The infusion time and cumulative dosage were 134 +/- 112 (6-480) hours and 111 +/- 94 (4-396) microg/Kg respectively."( [Complications of prostaglandin E1 treatment of congenital heart disease in paediatric medical intensive care].
Bosser, G; Burger, G; Chipaux, M; Feillet, F; Le Tacon, S; Lethor, JP; Lucron, H; Marçon, F; Monin, P, 2005
)
0.33
" Dose-response relations for PGE2 and subtype receptors EP1/EP3 (sulprostone), EP2 (butaprost), and EP4 (1-OH PGE1) were assessed by cumulated doses of single agonists."( Duodenal secretion in humans mediated by the EP4 receptor subtype.
Bindslev, N; Hansen, MB; Larsen, R, 2005
)
0.33
" Real time rigidity assessment was used for the objective determination of the initial dosage and then doses were regulated in order to introduce an erection suitable for penetration and maintenance of erection for approximately 30 min."( Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Athanasopoulos, A; Gyftopoulos, K; Kartsanis, G; Konstantinopoulos, A; Liatsikos, E; Perimeni, PP; Perimenis, P, 2006
)
0.33
" The key point for maintenance in treatment is the adjustment of the therapeutic method and dosage to optimal levels for satisfactory erections."( Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Athanasopoulos, A; Gyftopoulos, K; Kartsanis, G; Konstantinopoulos, A; Liatsikos, E; Perimeni, PP; Perimenis, P, 2006
)
0.33
"0001) at each dose level and at all post dosing time points."( Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy.
Costabile, R; Dietrich, J; Friedman, A; Gittelman, M; Guay, A; Heard-Davison, A; Heiman, JR; Peterson, C; Stephens, D, 2006
)
0.77
" The DGLA levels in the liver, serum, and brain significantly increased with increasing dosage of DGLA in the diet."( Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats.
Fujiwara, Y; Kawashima, H; Kiso, Y; Matsumoto, A; Morimitsu, Y; Ono, Y; Sagawa, S; Seyama, Y; Umeda-Sawada, R; Ushiyama, I, 2006
)
0.33
" The optimal dosage of limaprost for this indication was therefore deemed to be 15 microg/day."( Limaprost.
Plosker, GL; Swainston Harrison, T, 2007
)
0.34
" The dosage of 1000 microg was used for the third application by 65 % of the patients."( [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
Görlich, HD; Potempa, DM; Potempal, AJ; Stolpmann, RM, 2007
)
0.63
"In patients with chronic constipation, treatment with lubiprostone produces a BM in the majority of individuals within 24-48 h of initial dosing and improves the frequency as well as other characteristics associated with BMs with short-term (i."( Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
Geenen, J; Johanson, JF; Morton, D; Ueno, R, 2008
)
0.35
" The nausea may be alleviated or minimized by administering the dose with food, and some patients may require a dosage reduction to 24 mug once daily."( Lubiprostone: a new drug for the treatment of chronic idiopathic constipation.
Baker, DE, 2007
)
0.34
" A clear dose-response relationship was detected in all murine strains."( Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.
Hawkins, CE; Henderson, MJ; MacDonald, KD; McKenzie, KR; Vij, N; Zeitlin, PL, 2008
)
0.35
" Chronic dosing of oral type V phosphodiesterase inhibitors is now commonly used by urologists after radical prostatectomy despite a lack of convincing evidence from randomized, placebo-controlled clinical trials."( Local therapies to heal the penis: fact or fiction?
Kim, ED,
)
0.13
" Optimal injected dosage of each patient with positive reaction was determined."( [Real-time Rigiscan monitoring and color Doppler ultrasonography in the diagnosis of erectile dysfunction].
Chen, H; He, L; Jiang, X; Liu, Z; Tang, Y; Wen, J, 2009
)
0.35
" The dosage of PGE(1) following intracavernous injection is related to vascular ED."( [Real-time Rigiscan monitoring and color Doppler ultrasonography in the diagnosis of erectile dysfunction].
Chen, H; He, L; Jiang, X; Liu, Z; Tang, Y; Wen, J, 2009
)
0.35
" The dosing regimen was 400 microg as the initial dose followed by 400 microg up to 3 doses (1200 microg) if needed in each group."( Vaginal versus oral misoprostol for second-trimester pregnancy termination: a randomized trial.
Behrashi, M; Mahdian, M, 2008
)
0.35
" Meta-analysis was neither possible nor considered appropriate due to the differences in the type of vasodilators used, dosage and duration of treatment."( Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss.
Agarwal, L; Pothier, DD, 2009
)
0.35
" Moreover, there were differences in the type, dosage and duration of vasodilator used in each study."( Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss.
Agarwal, L; Pothier, DD, 2009
)
0.35
" Therefore, a preliminary PK study was designed at a clinical oral dosage of 30-microg limaprost in 5 healthy Korean volunteers."( Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers.
Kang, JS; Kim, SH; Lee, MH; Lee, YS; Park, JH; Park, YS; Yang, SC, 2010
)
0.36
"The volunteers were assigned randomly to four groups which received alprostadil cream in different dosage (500 μg, 700 μg and 900 μg) or placebo cream, respectively."( [Multicenter randomized, double-blind, placebo-controlled trial of prostaglandin E1 cream for female sexual arousal disorder].
Chen, L; Geng, L; Liao, QP; Lu, JL; Lv, MQ; Lv, T; Song, XH; Wang, QX; Wang, XP; Xia, B; Yao, C; Yao, YJ; Zhang, HZ; Zhang, M; Zhao, J, 2010
)
0.6
" In the PGE1-only group, the maintenance dosage was significantly correlated with preoperative sexual function and nerve sparing (NS) (P<0."( Experience with intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: dose considerations.
Cha, TL; Chuang, FP; Lakin, M; Montague, DK; Sun, GH; Wu, ST,
)
0.13
"Empiric dosing of gentamicin has not been evaluated in critically ill neonates with unrepaired congenital heart disease (CHD)."( Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease.
Moffett, BS; Rossano, JW, 2012
)
0.38
"To determine whether an empiric gentamicin dosing regimen for neonates achieves acceptable serum trough concentrations in neonatal patients with unrepaired CHD receiving alprostadil."( Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease.
Moffett, BS; Rossano, JW, 2012
)
0.57
"Current empiric gentamicin dosing regimens may not be appropriate for critically ill neonates with unrepaired CHD."( Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease.
Moffett, BS; Rossano, JW, 2012
)
0.38
" There is level 5 evidence (expert opinion) that combination therapy of PDE5 inhibitors + L-arginine or daily dosing of tadalafil + short-acting PDE5 inhibitors pro re nata may rescue PDE5 inhibitor monotherapy failures."( SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Brock, G; Burnett, A; Ghanem, H; Giuliano, F; Glina, S; Hellstrom, W; Martin-Morales, A; Porst, H; Salonia, A; Sharlip, I, 2013
)
0.39
" Polymeric porous particles of PGE1 produced the same effects at a reduced dosing frequency compared to plain PGE1 and caused minimal off-target effects on systemic hemodynamics."( Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.
Ahsan, F; Gupta, N; Gupta, V; Komatsu, M; McMurtry, IF; Mehvar, R; Nozik-Grayck, E; Oka, M; Shaik, IH, 2013
)
0.39
" There were no statistically significant differences in pharmacokinetic parameters for both single and multiple dosing between female and male subjects."( Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects.
Cao, Y; Chen, H; Ding, Y; Gu, J; Li, X; Liu, C; Sun, Y; Yin, L; Zhang, H; Zhang, Q, 2015
)
0.42
" Vaginal biopsies were evaluated at the end of dosing and recovery."( Daily application of alprostadil topical cream (Vitaros) does not impact vaginal pH, flora, or histology in female cynomolgus monkeys.
Debar, S; Meier-Davis, SR; Rabe, M; Siddoway, J,
)
0.45
" These data provide evidence for the read-across hypothesis, but suggest establishing a direct dose-response between internal plasma and PGEM is difficult, and would require significantly larger numbers of fish to overcome the inter-individual variation."( Testing the "read-across hypothesis" by investigating the effects of ibuprofen on fish.
Glennon, YC; Owen, SF; Panter, GH; Patel, A; Rand-Weaver, M; Sumpter, JP; Trollope, HT, 2016
)
0.43
"2), in absence of vascular risk factors, no responder to PDE5-I that undergone to PDDU by PII at high dosage (bimix: prostaglandin E1 20 mcg, papaverine 20 mg)."( Penile vascular diagnostic categorization using penile duplex Doppler ultrasound: Differences in vascular hemodynamics parameters by differences in anatomic sampling location.
Pezzoni, F; Scroppo, FI, 2016
)
0.43
" This review describes published literature on patients who failed to respond to an on-demand PDE5I regimen and were treated with a non-invasive PDEI-based regimen, including switching from one PDE5I to another; increasing the dose of PDE5I above the labeled dosage range; using two PDE5Is concurrently; using a daily PDE5I regimen; or combining a PDE5I with a testosterone supplement, α-adrenergic antagonist, intraurethral or intracavernosal alprostadil, vacuum erection device, or low-intensity shock wave therapy."( Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Lee, M; Sharifi, R, 2018
)
0.64
"Second trimester TOP on scarred uterus warrants careful usage of abortifacient with minimal cumulative dosage and should be carried out in early second trimester gestation whenever feasible."( Incidence and contributing factors for uterine rupture in patients undergoing second trimester termination of pregnancy in a large tertiary hospital - a 10-year case series.
Daniel Seow Choon, K; Eek Chaw, T; Hester Chang Qi, QL; Kok Hian, T; Mor Jack, NG; Wan Shi, T, 2018
)
0.48
" Twenty patients were enrolled in the study; two patients were excluded for poor penile turgidity after a maximum dosage of intracavernosal alprostadil."( Comparison of clinician and patient users of a mobile phone application to assess penile curvature in Peyronie's disease.
Brisbane, WG; Hsi, RS; Ostrowski, KA; Rajanahally, S; Rogers, MJ; Schade, GR; Trew, L; Walsh, TJ; Wessells, H, 2020
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
vasodilator agentA drug used to cause dilation of the blood vessels.
anticoagulantAn agent that prevents blood clotting.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins E
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Selenium micronutrient network095
Vitamin B12 metabolism050
Folate metabolism156

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency12.84680.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency6.69130.000221.22318,912.5098AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.11690.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.14640.000229.305416,493.5996AID743069; AID743075; AID743078; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency11.45540.001019.414170.9645AID743094; AID743140
Cellular tumor antigen p53Homo sapiens (human)Potency7.16690.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)26.90000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)2.30000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Thromboxane-A synthase Homo sapiens (human)Ki0.10000.10000.10000.1000AID160920
Prostaglandin E2 receptor EP3 subtypeMus musculus (house mouse)Ki0.00500.00500.01350.0560AID161064; AID161065; AID161066
Prostaglandin E2 receptor EP4 subtypeMus musculus (house mouse)Ki0.00330.00310.00320.0033AID161190; AID161191; AID161192
Prostaglandin E2 receptor EP1 subtypeMus musculus (house mouse)Ki0.03750.00600.02700.1000AID160920; AID160921; AID161036
Prostacyclin receptorHomo sapiens (human)Ki2.61250.00320.49586.6280AID161208; AID161209; AID161210
Prostaglandin E2 receptor EP2 subtypeMus musculus (house mouse)Ki0.04770.02200.03920.0870AID161050; AID161051; AID161052
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Solute carrier organic anion transporter family member 2B1Rattus norvegicus (Norway rat)IC50 (µMol)0.03580.03580.16140.2870AID679647
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin E2 receptor EP4 subtypeMus musculus (house mouse)EC50 (µMol)0.00290.00160.00250.0036AID161188; AID161189
Prostacyclin receptorHomo sapiens (human)EC50 (µMol)0.00180.00040.05450.3470AID161202
Nuclear receptor subfamily 4 group A member 2Homo sapiens (human)EC50 (µMol)3.00000.01002.89125.1000AID1885201; AID1885202
Nuclear receptor subfamily 4 group A member 2Mus musculus (house mouse)EC50 (µMol)3.00003.00004.00005.0000AID1885203; AID1885204
Nuclear receptor subfamily 4 group A member 2Rattus norvegicus (Norway rat)EC50 (µMol)3.00003.00004.00005.0000AID1885205; AID1885206
Prostaglandin E2 receptor EP2 subtypeMus musculus (house mouse)EC50 (µMol)0.00260.00260.00260.0026AID161048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 4Homo sapiens (human)Km2.10001.90004.27259.6900AID680356
Solute carrier organic anion transporter family member 2A1Rattus norvegicus (Norway rat)Km0.07000.07001.65207.5690AID681576
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)K1/20.08200.08200.10780.1820AID682149
Solute carrier organic anion transporter family member 3A1Homo sapiens (human)Km0.04850.04850.05200.0555AID681367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (208)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerProstacyclin receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayProstacyclin receptorHomo sapiens (human)
cell-cell signalingProstacyclin receptorHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayProstacyclin receptorHomo sapiens (human)
response to lipopolysaccharideProstacyclin receptorHomo sapiens (human)
negative regulation of smooth muscle cell proliferationProstacyclin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProstacyclin receptorHomo sapiens (human)
inflammatory responseProstacyclin receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to hypoxiaNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron migrationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to amphetamineNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-templated transcriptionNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
adult locomotory behaviorNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
post-embryonic developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system projection neuron axonogenesisNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
habenula developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to oxidative stressNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of dopamine metabolic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopamine biosynthetic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron maturationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of respiratory gaseous exchangeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
fat cell differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
general adaptation syndromeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
canonical Wnt signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
midbrain dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
positive regulation of protein phosphorylationSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
transport across blood-brain barrierSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (73)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
guanyl-nucleotide exchange factor activityProstacyclin receptorHomo sapiens (human)
prostacyclin receptor activityProstacyclin receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
beta-catenin bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein heterodimerization activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 3A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
cytosolProstacyclin receptorHomo sapiens (human)
plasma membraneProstacyclin receptorHomo sapiens (human)
plasma membraneProstacyclin receptorHomo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cytoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear speckNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein-containing complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Mus musculus (house mouse)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lysosomeSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 3A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (176)

Assay IDTitleYearJournalArticle
AID1346377Human DP1 receptor (Prostanoid receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:7
Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
AID1346396Rat EP3 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346318Rat EP2 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346448Human CatSper2 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID1346498Human CatSper4 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID1346303Mouse EP2 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346307Mouse EP4 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346350Human IP receptor (Prostanoid receptors)2007British journal of pharmacology, Oct, Volume: 152, Issue:4
New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues.
AID1346427Human EP4 receptor (Prostanoid receptors)2009The Journal of pharmacology and experimental therapeutics, Oct, Volume: 331, Issue:1
Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands.
AID1346308Human EP2 receptor (Prostanoid receptors)1994The Journal of biological chemistry, Apr-22, Volume: 269, Issue:16
Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype.
AID1346372Mouse EP1 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346345Rat EP1 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346353Rat EP4 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346336Mouse EP3 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346408Human EP1 receptor (Prostanoid receptors)2002The Journal of pharmacy and pharmacology, Apr, Volume: 54, Issue:4
Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques.
AID1346536Human CatSper3 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID1346427Human EP4 receptor (Prostanoid receptors)2000British journal of pharmacology, Aug, Volume: 130, Issue:8
Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
AID1346462Human CatSper1 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID1346350Human IP receptor (Prostanoid receptors)2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.
AID1346431Mouse IP receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID157016Inhibitory activity against ADP-induced platelet aggregation at concentration 10 ng/mL1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis of acylguanidine analogues: inhibitors of ADP-induced platelet aggregation.
AID1134519Bronchodilatory activity in iv dosed Hartley guinea pig assessed as inhibition of acetylcholine-induced constriction compound of total 3 to 4 doses at 15 mins interval starting first dose 2 mins post challenge1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Prostaglandins and congeners. 14. Synthesis and bronchodilator activity of dl-16,16-trimethyleneprostaglandins.
AID1135390Binding affinity to prostanoid receptor in [8-14C]-adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 0.1 ug/mL after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1134747Gastric antisecretory activity in iv dosed Mongrel dog with heidenhain pouch assessed as inhibition of histamine-induced total acid output by titrimetric method1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Synthesis and gastric antisecretory properties of 15-deoxy-16-hydroxyprostaglandin E analogues.
AID1146117Displacement of [3H-PGE1] from Sprague-Dawley rat kidney prostaglandin receptor after 60 mins by scintillation counting analysis1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID1146128Stimulation of prostanoid receptor-mediated cAMP-[14C] production in Charles River CD-1 mouse ovary at 10 ug/ml preincubated with adenine-8-[14C] for 1 hr followed by compound addition measured after 30 mins in presence of theophylline relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID1885204Agonist activity at Nurr1 in mouse MN9D cells measured by Gal4-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID160921Evaluated for its competitive binding affinity towards mouse Prostanoid EP1 receptor in CHO cells expressing prostanoid receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.
AID157019Inhibitory activity against ADP-induced platelet aggregation at concentration 32 ng/mL1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis of acylguanidine analogues: inhibitors of ADP-induced platelet aggregation.
AID679647TP_TRANSPORTER: inhibition of PGD2 uptake in Xenopus laevis oocytes2000Biochemical and biophysical research communications, Sep-07, Volume: 275, Issue:3
Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.
AID1135434Binding affinity to prostanoid receptor in [8-14C]adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 1 ug/ml after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline relative to cont1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
11,12-Secoprostaglandins. 3. 8-Alkylthio(sulfinyl and sulfonyl)-12-hydroxyalkanoic acids and related compounds.
AID161050Binding affinity towards mouse Prostanoid EP2 receptor expressed in CHO cells.2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP2-receptor agonist.
AID1885205Agonist activity at Nurr1 in rat N27-A cells measured by NBRE-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID161188Effective concentration which increases intracellular c-AMP production in mouse Prostanoid EP4 receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.
AID161209Evaluated for its competitive binding affinity towards human Prostanoid IP receptor in CHO cells2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.
AID1135453Inhibition of antigen-induced lymphocyte (unknown origin) transformation at 10 ug/mL relative to control1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
11,12-Secoprostaglandins. 3. 8-Alkylthio(sulfinyl and sulfonyl)-12-hydroxyalkanoic acids and related compounds.
AID1133293Antisecretory activity in rat assessed as decrease in volume of gastric secretion at 1.5 mg/kg, sc immediately after surgery and again 2 hrs later measured after 4 hrs of pyloric ligation1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and gastric antisecretory properties of an 8-aza-and a 10-oxa-8,12-secoprostaglandin.
AID232557Ratio of ED50 for diarrhea to ID50 (antisecretory activity)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Structure-activity studies of 16-methoxy-16-methyl prostaglandins.
AID1146120Binding affinity to prostaglandin receptor in Charles River CD-1 mouse ovary assessed as increase in cAMP accumulation using [8-14C]adenine at 0.1 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID681576TP_TRANSPORTER: uptake in PGT-expressing HeLa cells1995Science (New York, N.Y.), May-12, Volume: 268, Issue:5212
Identification and characterization of a prostaglandin transporter.
AID1135437Binding affinity to prostanoid receptor in [8-14C]adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 0.01 ug/ml after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline relative to c1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
11,12-Secoprostaglandins. 3. 8-Alkylthio(sulfinyl and sulfonyl)-12-hydroxyalkanoic acids and related compounds.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID84688Antifertility activity was determined in hamsters (two to six dose levels, 6-18 animals per group) treated subcutaneously (sc) from day 4 to day 6 of gestation.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Structure-activity studies of 16-methoxy-16-methyl prostaglandins.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1146125Stimulation of prostanoid receptor-mediated cAMP-[14C] production in Charles River CD-1 mouse ovary at 0.05 ug/ml preincubated with adenine-8-[14C] for 1 hr followed by compound addition measured after 30 mins in presence of theophylline relative to contr1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID160920Binding affinity towards mouse Prostanoid EP1 receptor in CHO cells.2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP2-receptor agonist.
AID161036Affinity for mouse Prostanoid EP1 receptor expressed in CHO cells2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID157018Inhibitory activity against ADP-induced platelet aggregation at concentration 3.2 ng/mL1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis of acylguanidine analogues: inhibitors of ADP-induced platelet aggregation.
AID1135391Binding affinity to prostanoid receptor in [8-14C]-adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 1 ug/mL after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1146131Antithrombotic activity in po dosed guinea pig assessed as inhibition of collagen-induced platelet aggregation1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID161208Binding affinity towards human Prostanoid IP receptor in CHO cells.2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP2-receptor agonist.
AID1145966Stimulation of prostanoid receptor-mediated cAMP accumulation in Charles River CD-1 mouse ovary at 0.05 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 2. N-acyl-N-alkyl-7-aminoheptanoic acids.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1135438Binding affinity to prostanoid receptor in [8-14C]adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 0.05 ug/ml after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline relative to c1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
11,12-Secoprostaglandins. 3. 8-Alkylthio(sulfinyl and sulfonyl)-12-hydroxyalkanoic acids and related compounds.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1135395Renal vasodilatory activity in dog assessed as increase in renal blood flow administered through infusion into renal artery1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds.
AID1134518Bronchodilatory activity in iv dosed Hartley guinea pig assessed as inhibition of histamine-induced constriction compound of total 3 to 4 doses at 15 mins interval starting first dose 2 mins post challenge1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Prostaglandins and congeners. 14. Synthesis and bronchodilator activity of dl-16,16-trimethyleneprostaglandins.
AID1146116Binding affinity to prostaglandin receptor in Charles River CD-1 mouse ovary assessed as increase in cAMP accumulation using [8-14C]adenine at 100 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1135858Induction of Prostaglandin receptor-induced adenylate cyclase activation in rat liver homogenate assessed as increase in cAMP level at 2.8 x 10'-5 mol/L after 10 mins relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and prostaglandin-like activity of 2-(trans-3-hydroxy-1-octenyl)-3-indoleheptanoic acid.
AID1135439Binding affinity to prostanoid receptor in [8-14C]adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 0.1 ug/ml after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline relative to co1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
11,12-Secoprostaglandins. 3. 8-Alkylthio(sulfinyl and sulfonyl)-12-hydroxyalkanoic acids and related compounds.
AID161192Affinity for mouse Prostanoid EP4 receptor expressed in CHO cells2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID1146126Stimulation of prostanoid receptor-mediated cAMP-[14C] production in Charles River CD-1 mouse ovary at 0.1 ug/ml preincubated with adenine-8-[14C] for 1 hr followed by compound addition measured after 30 mins in presence of theophylline relative to contro1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1135445Binding affinity to prostanoid receptor in [8-14C]adenine-treated human psoriatic skin slices assessed as increase in c-AMP production at 10 ug/ml after 30 mins by paper chromatographic analysis relative to control1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
11,12-Secoprostaglandins. 3. 8-Alkylthio(sulfinyl and sulfonyl)-12-hydroxyalkanoic acids and related compounds.
AID1150975Gastric antisecretory activity in iv dosed Mongrel dog with heidenhain pouches assessed as inhibition of histamine-induced total acid output administered as single bolus dose at 1 hr post histamine challenge1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological evaluation of omega-homologues of prostaglandin E1.
AID1146118Binding affinity to prostaglandin receptor in Charles River CD-1 mouse ovary assessed as increase in cAMP accumulation using [8-14C]adenine at 0.01 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID1146121Binding affinity to prostaglandin receptor in Charles River CD-1 mouse ovary assessed as increase in cAMP accumulation using [8-14C]adenine at 10 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID1146132Antithrombotic activity in ip dosed guinea pig assessed as inhibition of collagen-induced platelet aggregation1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID161052Affinity for mouse Prostanoid EP2 receptor expressed in CHO cells2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1134523Bronchodilatory activity in anesthetized dog assessed as inhibition of pilocarpine-induced bronchospasms compound administered through aerosol 15 mins post challenge measured up to 1 hr1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Prostaglandins and congeners. 14. Synthesis and bronchodilator activity of dl-16,16-trimethyleneprostaglandins.
AID161051Evaluated for its competitive binding affinity towards mouse Prostanoid EP2 receptor in CHO cells expressing prostanoid receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.
AID1135396Inhibition of collagen-induced platelet aggregation in po dosed guinea pig1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1146115Binding affinity to prostaglandin receptor in Charles River CD-1 mouse ovary assessed as increase in cAMP accumulation using [8-14C]adenine at 25 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1135388Binding affinity to prostanoid receptor in [8-14C]-adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 0.01 ug/mL after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds.
AID182629Compound was evaluated for antisecretion activity using stomach perfusion test in the anesthetized rat (iv administration)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Structure-activity studies of 16-methoxy-16-methyl prostaglandins.
AID161189Effective concentration for increased intracellular c-AMP production by mouse Prostanoid EP4 receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID679297TP_TRANSPORTER: uptake in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID1134517Bronchodilatory activity in iv dosed Hartley guinea pig assessed as inhibition of serotonin-induced constriction compound of total 3 to 4 doses at 15 mins interval starting first dose 2 mins post challenge1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Prostaglandins and congeners. 14. Synthesis and bronchodilator activity of dl-16,16-trimethyleneprostaglandins.
AID1135389Binding affinity to prostanoid receptor in [8-14C]-adenine-treated CD-1 mouse ovary assessed as increase in c-AMP production at 0.05 ug/mL after 30 mins by paper chromatographic analysis in presence of phosphodiesterase inhibitor theophylline1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID161190Binding affinity towards mouse Prostanoid EP4 receptor in CHO cells.2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP2-receptor agonist.
AID161065Evaluated for its competitive binding affinity towards mouse Prostanoid EP3 receptor in CHO cells expressing prostanoid receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146129Stimulation of prostanoid receptor-mediated cAMP-[14C] production in Charles River CD-1 mouse ovary at 25 ug/ml preincubated with adenine-8-[14C] for 1 hr followed by compound addition measured after 30 mins in presence of theophylline relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID161210Affinity for human Prostanoid IP receptor expressed in CHO cells2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID161048Effective concentration which increases intracellular c-AMP production in mouse Prostanoid EP2 receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP2-receptor agonist.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1145967Stimulation of prostanoid receptor-mediated cAMP accumulation in Charles River CD-1 mouse ovary at 0.1 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 2. N-acyl-N-alkyl-7-aminoheptanoic acids.
AID1885202Agonist activity at Nurr1 in human SK-N-BE(2)-C cells measured by Gal4-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1146127Stimulation of prostanoid receptor-mediated cAMP-[14C] production in Charles River CD-1 mouse ovary at 1 ug/ml preincubated with adenine-8-[14C] for 1 hr followed by compound addition measured after 30 mins in presence of theophylline relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID1135397Inhibition of collagen-induced platelet aggregation in ip dosed guinea pig1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1145968Stimulation of prostanoid receptor-mediated cAMP accumulation in Charles River CD-1 mouse ovary at 1 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
11,12-Secoprostaglandins. 2. N-acyl-N-alkyl-7-aminoheptanoic acids.
AID1146130Stimulation of prostanoid receptor-mediated cAMP-[14C] production in Charles River CD-1 mouse ovary at 100 ug/ml preincubated with adenine-8-[14C] for 1 hr followed by compound addition measured after 30 mins in presence of theophylline relative to contro1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID681367TP_TRANSPORTER: uptake in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1135763Inhibition of bovine collagen-induced platelet aggregation isolated from ip treated Hartley guinea pig after 1 hr treatment1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
11,12-Secoprostaglandins. 5. 8-Acetyl- or 8-(1-hydroxyethyl)-12-hydroxy-13-aryloxytridecanoic acids and sulfonamide isosteres as inhibitors of platelet aggregation.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID129964Compound was evaluated for diarrheal effect in mice (po administration)1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Structure-activity studies of 16-methoxy-16-methyl prostaglandins.
AID1133294Antisecretory activity in rat assessed as decrease in total acid at 1.5 mg/kg, sc immediately after surgery and again 2 hrs later measured after 4 hrs of pyloric ligation1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and gastric antisecretory properties of an 8-aza-and a 10-oxa-8,12-secoprostaglandin.
AID1135759Induction of prostaglandin-like activity in CD-1 mouse ovary assessed as fold increase in [14C]-cAMP formation using ATP-[14C] substrate at 10 ug/ml after 30 mins incubation by PG assay1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
11,12-Secoprostaglandins. 5. 8-Acetyl- or 8-(1-hydroxyethyl)-12-hydroxy-13-aryloxytridecanoic acids and sulfonamide isosteres as inhibitors of platelet aggregation.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID680356TP_TRANSPORTER: uptake (vesicle) in membrane vesicles from MRP4-expressing Sf9 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID1885203Agonist activity at Nurr1 in mouse MN9D cells measured by NBRE-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1885206Agonist activity at Nurr1 in rat N27-A cells measured by Gal4-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1146124Stimulation of prostanoid receptor-mediated cAMP-[14C] production in Charles River CD-1 mouse ovary at 0.01 ug/ml preincubated with adenine-8-[14C] for 1 hr followed by compound addition measured after 30 mins in presence of theophylline relative to contr1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
11,12-secoprostaglandins. 4. 7-(N-alkylmethanesulfonamido) heptanoic acids.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID161202Effective concentration which increases intracellular c-AMP production in human Prostanoid IP receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP2-receptor agonist.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID157035Concentration required to inhibit in vitro ADP-induced platelet aggregation in human platelet rich plasma relative PGE11989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis of acylguanidine analogues: inhibitors of ADP-induced platelet aggregation.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID681173TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000Biochemical and biophysical research communications, Sep-07, Volume: 275, Issue:3
Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.
AID1146119Binding affinity to prostaglandin receptor in Charles River CD-1 mouse ovary assessed as increase in cAMP accumulation using [8-14C]adenine at 0.05 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID161066Affinity for mouse Prostanoid EP3 receptor expressed in CHO cells2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1885201Agonist activity at Nurr1 in human SK-N-BE(2)-C cells measured by NBRE-based luciferase reporter gene assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1409746Clearance in human2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs.
AID681219TP_TRANSPORTER: inhibition of PGE2 uptake (PGE2: 0.015 uM) by Prostaglandin E1 at 0.15uM in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID161191Evaluated for its competitive binding affinity towards mouse Prostanoid EP4 receptor in CHO cells expressing prostanoid receptor2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.
AID681873TP_TRANSPORTER: inhibition of alaninyl-d4TMP by Prostaglandin E1 at a concentration of 20uM in membrane vesicle from MRP5-expressing HEK293 cell2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID682149TP_TRANSPORTER: uptake in PGT-expressing HeLa cells1996The Journal of clinical investigation, Sep-01, Volume: 98, Issue:5
Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT).
AID156874Inhibitory concentration required to inhibit ADP-induced platelet aggregation in human platelet rich plasma1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis of acylguanidine analogues: inhibitors of ADP-induced platelet aggregation.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1146114Binding affinity to prostaglandin receptor in Charles River CD-1 mouse ovary assessed as increase in cAMP accumulation using [8-14C]adenine at 1 ug/ml after 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Prostaglandin isosteres. 1. (8-Aza-, 8,10-diaza-, and 8-aza-11-thia)-9-oxoprostanoic acids and their derivatives.
AID161064Binding affinity towards mouse Prostanoid EP3 receptor in CHO cells.2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Design and synthesis of a highly selective EP2-receptor agonist.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,734)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902252 (33.44)18.7374
1990's2399 (35.63)18.2507
2000's1231 (18.28)29.6817
2010's668 (9.92)24.3611
2020's184 (2.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.64 (24.57)
Research Supply Index8.99 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index172.85 (26.88)
Search Engine Supply Index2.89 (0.95)

This Compound (65.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials864 (12.11%)5.53%
Reviews520 (7.29%)6.00%
Case Studies417 (5.84%)4.05%
Observational9 (0.13%)0.25%
Other5,326 (74.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (58)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Unicentric, Randomized, Parallel, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy [NCT03851562]Phase 224 participants (Anticipated)Interventional2018-06-13Recruiting
Preservation of Penile Tumescence by Cavernous Tissue Preservation During Penile Prosthesis Implantation [NCT03733860]100 participants (Anticipated)Interventional2018-11-01Active, not recruiting
The Safety, Tolerability and Pharmacokinetic Phrase I Study of Alprostadil Fat Emulsiom Injection in Healthy Adult Volunteers [NCT03669562]Phase 148 participants (Anticipated)Interventional2018-08-07Recruiting
Evaluation of an Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia (NOMI) [NCT04235634]42 participants (Actual)Observational [Patient Registry]2018-10-01Completed
Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure [NCT03682952]Phase 4100 participants (Anticipated)Interventional2018-02-01Active, not recruiting
A Multicenter, Randomized, Open-label Phase II Clinical Trial Evaluating Alprostadil Liposomal Injection in the Prevention of Contrast-induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention [NCT05475717]Phase 2368 participants (Anticipated)Interventional2022-10-20Recruiting
Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy [NCT01378845]30 participants (Anticipated)Interventional2011-07-31Recruiting
Comparison of Two Protocols of Misoprostol (PGE1) and Their Effect on the Rate of Cesarean Section Due to Failed Induction. A Randomized, Controlled Trial. [NCT03489798]310 participants (Actual)Interventional2018-04-05Completed
[NCT02574338]135 participants (Actual)Interventional2015-09-30Completed
Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke [NCT03252626]Phase 4950 participants (Anticipated)Interventional2022-08-18Not yet recruiting
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma) [NCT02228850]Phase 235 participants (Actual)Interventional2014-11-30Completed
Comparison of Vaginal Versus Sublingual Misoprostol in the Treatment of First Trimester Missed Miscarriage [NCT04604366]Phase 2120 participants (Actual)Interventional2020-11-02Completed
Evaluation of the Effect of Rectal Misoprostol on Blood Loss During Abdominal Hysterectomy: A Double Blind Randomized Controlled Trial. [NCT02265562]Phase 3220 participants (Anticipated)Interventional2014-10-31Recruiting
A 52-week Multicenter, Randomized, Double-blind, Prospective Study to Evaluate Comparative Effectiveness and Safety of Alprostadil Injection,Sodium Ferulate and Dopamine Injection in Pediatric Acute Kidney Injury [NCT03892447]Phase 4300 participants (Anticipated)Interventional2019-08-01Not yet recruiting
Effect Of Prostaglandin E1 Treatment On Pyloric Wall Thickness in Newborns With Ductal Dependent Critical Congenital Heart Diseases [NCT04496050]20 participants (Anticipated)Observational [Patient Registry]2019-05-06Active, not recruiting
The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers [NCT02889822]Phase 144 participants (Actual)Interventional2010-03-31Completed
SUB LINGUAL MISOPROSTOL PRIOR TO IUD INSERTION IN WOMEN WITH ONLY PREVIOUS CESARIAN SECTION: A Randomized Controlled Trial [NCT02141321]Phase 2/Phase 3124 participants (Actual)Interventional2014-05-31Completed
Labor Induction and Maternal BMI: Comparison of Different Pre-induction Cervical Ripening Methods: The Cook Double Balloon Catheter vs PGE1 Tablets in Lean, Overweight, and Obese Women. A Prospective Randomized Study. [NCT02223949]Phase 2/Phase 3624 participants (Anticipated)Interventional2014-10-31Not yet recruiting
Extracorporeal Shockwave Therapy in the Treatment for Erectile Dysfunction in Male Renal Transplant Recipients [NCT02412345]20 participants (Actual)Interventional2015-01-31Completed
A Randomized, Double-Blind, Comparative, Multi-Center, Phase Ⅳ Clinical Trial to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis [NCT01888536]Phase 4182 participants (Actual)Interventional2013-02-28Completed
Confirmatory, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Dry Age-related Macular Degeneration. [NCT00619229]Phase 337 participants (Actual)Interventional2006-07-31Terminated(stopped due to Interim Analysis: Optimization of study design required.)
Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery [NCT00733434]Phase 4242 participants (Anticipated)Interventional2008-07-31Recruiting
Phase 3 Study of Alprostadil Continuous Intravenous Infusion to Maintain Clinical Stability in Severe Heart Failure Patients [NCT00610051]Phase 31,500 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Letrozole Plus Misoprostol Versus Misoprostol Alone in Induction of Abortion of Anembryonic Pregnancy: [NCT05198050]96 participants (Actual)Interventional2022-04-03Completed
In Vitro Myometrial Contractions in Laboring and Non-laboring Women: Oxytocin is Superior to Other Uterotonic Agents [NCT01689311]53 participants (Actual)Interventional2009-03-31Completed
Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities-A Phase II Multi-center Randomised Controlled Trial [NCT02877173]Phase 2160 participants (Anticipated)Interventional2016-08-31Recruiting
Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) [NCT00596752]Phase 4840 participants (Actual)Interventional2004-03-31Completed
Phase II, Single Center, Non-Controlled, Open-Label Study of Liposomal Prostaglandin E1 (Liprostin) as Adjunct Therapy With Lower Limb Angioplasty in Patients With Ischemic and Non-Ischemic Peripheral Arterial Occlusive Disease [NCT00053716]Phase 212 participants Interventional2003-02-28Recruiting
Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran of Phase II Clinical Trial [NCT04197323]Phase 220 participants (Anticipated)Interventional2019-10-01Recruiting
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network [NCT00598429]Phase 20 participants (Actual)Interventional2008-05-31Withdrawn(stopped due to Withdrawn due to lack of recruitment)
Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication [NCT01263925]Phase 3561 participants (Actual)Interventional2001-04-30Completed
Efficacy and Safety Study of Using Oral Sildenafil and Intracavernosal Alprostadil Injection as a Combined Pharmacotherapy for Men With Difficult to Treat Erectile Dysfunction. [NCT00507286]20 participants (Anticipated)Interventional2007-05-31Active, not recruiting
Efficacy of Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Patients With Critical Limb Ischemia. [NCT04312555]Phase 430 participants (Anticipated)Interventional2020-04-01Not yet recruiting
A Study to Assess the Relative Efficacy and Safety of a Single Dose of Alprostadil Cream Combined With 2 Concentrations of WC3036 Compared to Vehicle in Subjects With Erectile Dysfunction [NCT01810575]Phase 216 participants (Actual)Interventional2013-02-28Terminated(stopped due to Re-assessment of study)
Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization [NCT01722513]Phase 4150 participants (Anticipated)Interventional2012-11-30Active, not recruiting
Trial of Inhaled Alprostadil to Improve Hypoxia and Pulmonary Hypertension [NCT00314548]67 participants (Actual)Interventional2006-05-31Completed
Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention [NCT01245855]Phase 3100 participants (Anticipated)Interventional2011-01-31Not yet recruiting
A Randomized Phase II Trial Evaluating the Importance of Early Erectile Dysfunction Rehabilitation and Unilateral Autologous Sural Nerve Sparing Radical Prostatectomy Clinically Localized Prostate Cancer [NCT00080808]Phase 2111 participants (Actual)Interventional2001-08-31Completed
Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients [NCT02628106]Phase 421 participants (Actual)Interventional2015-12-31Completed
A Double-Blind, Randomized, 6-Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women With Female Sexual Arousal Disorder (FSAD) [NCT00324948]Phase 2300 participants Interventional2004-09-30Completed
A Phase 4, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction. [NCT01776320]Phase 40 participants (Actual)Interventional2013-12-31Withdrawn(stopped due to No medication)
Neurofeedback-enhanced Mindfulness Meditation for the Treatment of Affective and Attentional Disturbances in Patients With Traumatic Brain Injury [NCT02615535]25 participants (Actual)Interventional2015-12-31Completed
A Randomized Trial of Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy [NCT00955929]76 participants (Actual)Interventional2009-08-06Terminated(stopped due to The study was interrupted because of failure to recruit the target study population in a reasonable timeframe.)
The Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow After the Bidirectional Cavopulmonary Connection [NCT04054115]Phase 110 participants (Actual)Interventional2019-07-23Terminated(stopped due to Covid 19 and difficulty with recruitment)
Effectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19 [NCT04536363]Phase 20 participants (Actual)Interventional2020-12-03Withdrawn(stopped due to Delays in approval by the national regulatory authority)
Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section [NCT04780412]Phase 3210 participants (Actual)Interventional2020-09-01Active, not recruiting
IUD Insertion in Nulliparous Women: A Randomized, Placebo-Controlled Trial of Misoprostol for Cervical Priming [NCT01422226]3 participants (Actual)Interventional2011-07-31Terminated(stopped due to Unable to recruit participants)
Open-label, Single Center, Randomized Clinical Trial to Evaluate Safety, Efficacy of Eglandin® (Alprostadil) 360㎍, 720㎍ in Living Donor Liver Transplanted Patient [NCT02350218]Phase 276 participants (Anticipated)Interventional2015-03-31Active, not recruiting
Efficacy of Intracoronary Infusion of Different Medicine With Targeted Perfusion Catheter on Myocardial Perfusion in Patients With STEMI Undergoing Primary PCI:an Open,Prospective,Randomized,Multicenter Trial. [NCT03252665]Phase 4600 participants (Anticipated)Interventional2017-09-01Not yet recruiting
Vaginal Misoprostol Before Elective Cesarean Section to Improve Neonatal Respiratory Outcomes . Randomized Controlled Clinical Study [NCT03239327]292 participants (Anticipated)Interventional2016-06-30Recruiting
Efficacy and Safety of Sublingual Versus Vaginal Misoprostol for Induction of Labor for Primigravida at 41 or More Weeks of Pregnancy: A Randomized Clinical Trial [NCT04887493]500 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Effectiveness of Oral Versus Vaginal Misoprostol Before Office Hyteroscopy in Infertile Patients [NCT02409407]Phase 2120 participants (Anticipated)Interventional2015-04-30Recruiting
Prospective Observational Study of the Changes of Blood Flow of Arterial Anastomosis-site of Free Flap in Diabetic Patients Who Undergoing Free Flap Transfer [NCT03027219]44 participants (Actual)Observational2017-01-31Completed
Erectile Dysfunction Recovery in Men Age NCT00544076]Phase 3110 participants (Actual)Interventional2006-01-31Terminated(stopped due to Accrual too slow)
Pilot Randomized Clinical Trial of Inhaled PGE1 in Neonates With Sub-Optimal Response to Inhaled Nitric Oxide [NCT01467076]Phase 27 participants (Actual)Interventional2011-11-30Terminated(stopped due to The study was halted due to futility concerns based on the unmet benchmarks as specified in the pilot study protocol.)
Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon [NCT03296670]Phase 457 participants (Actual)Interventional2015-08-01Completed
A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus [NCT03159559]Phase 460 participants (Anticipated)Interventional2017-01-31Active, not recruiting
A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO) [NCT02895373]Phase 250 participants (Actual)Interventional2016-07-31Terminated(stopped due to After completion of pilot study (n=50) no effect on primary outcome and limited feasibility of recruitment and study procedures)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00544076 (4) [back to overview]Potency Rates (Ability to Obtain an Erection Sufficient for Penetration) Without Assistance Compared Between Patients in All Three Arms of the Study at 12 Months
NCT00544076 (4) [back to overview]Penile Length
NCT00544076 (4) [back to overview]Potency Rates With or Without Assistance in the Control Group Versus Maintenance MUSE or Maintenance Viagra
NCT00544076 (4) [back to overview]SHIMS-5 Scores in the Control Groups Versus Maintenance MUSE or Maintenance Viagra Groups
NCT00596752 (12) [back to overview]Intensity of Rest Pain Induced by Ischemic Lesions at 24 Weeks After the End of Study Drug Treatment
NCT00596752 (12) [back to overview]All-cause Mortality During the Course of the Study (up to 196 Days)
NCT00596752 (12) [back to overview]Cardiovascular Mortality During the Course of the Study (up to 196 Days)
NCT00596752 (12) [back to overview]Complete Healing of Ischemic Necroses and Ulcerations at 24 Weeks After the End of Study Drug Treatment
NCT00596752 (12) [back to overview]Minor Amputations at 24 Weeks After the End of Study Drug Treatment
NCT00596752 (12) [back to overview]Revascularization Procedures at 24 Weeks After the End of Study Drug Treatment
NCT00596752 (12) [back to overview]Cardiovascular Morbidity During the Course of the Study (up to 196 Days)
NCT00596752 (12) [back to overview]Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment
NCT00596752 (12) [back to overview]Consumption and Type of Analgesic Medication During the Course of the Study (up to 196 Days)
NCT00596752 (12) [back to overview]Increase/Decrease in Ulcer Area of ≥ 50 % at 24 Weeks After the End of Study Drug Treatment
NCT00596752 (12) [back to overview]Occurrence of Major Amputations at 24 Weeks After the End of Study Drug Treatment
NCT00596752 (12) [back to overview]Systolic Pressure at Ankle Level at 24 Weeks After the End of Study Drug Treatment
NCT00619229 (11) [back to overview]The Difference in Contrast Sensitivity Between Measurements at 3 Months After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]The Difference in Contrast Sensitivity Between Measurements at 6 Months After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]The Difference in Contrast Sensitivity Between Measurements Immediately After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]The Difference in Visual Acuity Between Measurements at 6 Months After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]The Difference in Visual Acuity Between Measurements Immediately After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]Development of a Wet Age-related Macular Degeneration
NCT00619229 (11) [back to overview]Difference in Visual Acuity Between Measurements at 3 Months After Drug Intervention and Measurements at Baseline (Assessed Within Early Treatment Diabetic Retinopathy Study (ETDRS) Chart)
NCT00619229 (11) [back to overview]The Difference in Color Vision Between Measurements at 3 Months After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]The Difference in Color Vision Between Measurements at 6 Months After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]The Difference in Color Vision Between Measurements Immediately After Intervention and Measurements at Baseline
NCT00619229 (11) [back to overview]Progression of the Dry Age-related Macular Degeneration
NCT01263925 (14) [back to overview]Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 2
NCT01263925 (14) [back to overview]Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings at Baseline
NCT01263925 (14) [back to overview]Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at Baseline
NCT01263925 (14) [back to overview]Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings After Period 1
NCT01263925 (14) [back to overview]Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline
NCT01263925 (14) [back to overview]Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 1
NCT01263925 (14) [back to overview]Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 2
NCT01263925 (14) [back to overview]Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline
NCT01263925 (14) [back to overview]Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 1
NCT01263925 (14) [back to overview]Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 3
NCT01263925 (14) [back to overview]Ratio of Maximum Walking Distance After Period 1 in Comparison With the Findings at Baseline
NCT01263925 (14) [back to overview]Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings After Period 1
NCT01263925 (14) [back to overview]Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings at Baseline
NCT01263925 (14) [back to overview]Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 1
NCT01422226 (1) [back to overview]Ease of IUD Insertion (Use of Ancillary Measures)
NCT01467076 (10) [back to overview]Change in Oxygenation Index (OI)
NCT01467076 (10) [back to overview]Change in Partial Pressure of Oxygen in the Blood (PaO2)
NCT01467076 (10) [back to overview]Death
NCT01467076 (10) [back to overview]Duration of iNO Therapy
NCT01467076 (10) [back to overview]Duration of Mechanical Ventilation
NCT01467076 (10) [back to overview]Feasibility Assessed as the Number of Participants Who Were Enrolled in the Study
NCT01467076 (10) [back to overview]Length of Hospital Stay
NCT01467076 (10) [back to overview]Need for Extracorporeal Membrane Oxygenation (ECMO)
NCT01467076 (10) [back to overview]Need for Inhaled Nitric Oxide (INO) 72 Hours After INO
NCT01467076 (10) [back to overview]Number of Days of Supplemental Oxygen (O2) Used
NCT02615535 (8) [back to overview]Change in Neurobehavioral Symptom Inventory
NCT02615535 (8) [back to overview]Change in Percentage of EEG Activity Associated With Alpha, Beta, and Theta Rhythms as Measured by Surface Electrodes on the MUSE Device
NCT02615535 (8) [back to overview]Change in Trail Making Test
NCT02615535 (8) [back to overview]Change in Wechsler Adult Intelligence Scale-IV Digit Span
NCT02615535 (8) [back to overview]Change in Wechsler Adult Intelligence Scale-IV Digit Symbol Coding
NCT02615535 (8) [back to overview]Change in Beck Anxiety Inventory
NCT02615535 (8) [back to overview]Change in Beck Depression Inventory-II
NCT02615535 (8) [back to overview]Change in Cognitive and Affective Mindfulness Scale-Revised
NCT02628106 (1) [back to overview]the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI

Potency Rates (Ability to Obtain an Erection Sufficient for Penetration) Without Assistance Compared Between Patients in All Three Arms of the Study at 12 Months

Potency rates (ability to obtain an erection sufficient for penetration) without assistance in those patients receiving maintenance Viagra compared to non-pharmacology controls was compared at 12 months from start of treatment using the fisher's exact test (NCT00544076)
Timeframe: 12 months following BNS-RAP

InterventionParticipants (Count of Participants)
Sildenafil Citrate/Mo+Aprostadil/Day13
Sildenafil Citrate Monthly16
Daily Sildenafil Citrate16

[back to top]

Penile Length

measurement of penile length in centimeters (NCT00544076)
Timeframe: At pre-treatment and 18 months

,,
Interventioncentimeters (Median)
Baseline Penile MeasurementMonth 18 Penile Measurement
Daily Sildenafil Citrate10.212
Sildenafil Citrate Monthly1211
Sildenafil Citrate/Mo+Aprostadil/Day1112.5

[back to top]

Potency Rates With or Without Assistance in the Control Group Versus Maintenance MUSE or Maintenance Viagra

Potency rates with or without assistance in the control group versus maintenance MUSE or maintenance Viagra were compared at each of 6 and 18 months (NCT00544076)
Timeframe: At 6 and 18 months

,,
InterventionParticipants (Count of Participants)
6 month potency18 month potency
Daily Sildenafil Citrate1715
Sildenafil Citrate Monthly1116
Sildenafil Citrate/Mo+Aprostadil/Day1014

[back to top]

SHIMS-5 Scores in the Control Groups Versus Maintenance MUSE or Maintenance Viagra Groups

Median and range of SHIM scores evaluated at 1, 3, 6, 9, 12, and 18 months. SHIMS-5 is the Sexual Health Inventory for Men, which includes 5 questions that are scored from 1 to 5 each. The total score is obtained by adding all five response scores, and can range from 5 to 25 when all 5 questions are answered. Questions that are left unanswered are scored as a 0, and can result in an overall score lower than 5 (as low as 0). Higher scores are more desirable. A Score of 22-25 = no ED, 17-21=Mild ED, 12-16=Mild to moderate ED, 8-11=Moderate ED, and 5-7 =Severe ED (ED=Erectile Dysfunction). There are no sub-scale scores within this questionnaire. (NCT00544076)
Timeframe: At 1, 3, 6, 9, 12, and 18 months

,,
Interventionunits on a scale (Median)
SHIM score 1 monthSHIM score 3 monthsSHIM score 6 monthsSHIM score 9 monthsSHIM score 12 monthsSHIM score 18 months
Daily Sildenafil Citrate121820191820.5
Sildenafil Citrate Monthly31418.517.51920
Sildenafil Citrate/Mo+Aprostadil/Day9.5141818.52019.5

[back to top]

Intensity of Rest Pain Induced by Ischemic Lesions at 24 Weeks After the End of Study Drug Treatment

"Visit values of intensity of rest pain from a visual analogue scale, ranging from 0 mm (no pain) to 100 mm (maximum conceivable pain), had to be reported in the case of presence of rest pain only. If the leading question in regard to the presence of rest pain is answered with No and no visit value is specified, the visit value will be set to 0 for the analysis." (NCT00596752)
Timeframe: At 24 weeks after the end of study drug treatment

Interventionmillimeters (mm) (Mean)
Alprostadil17.57
Placebo16.38

[back to top]

All-cause Mortality During the Course of the Study (up to 196 Days)

(NCT00596752)
Timeframe: During the course of the study (up to 196 days)

Interventionparticipants (Number)
Alprostadil20
Placebo15

[back to top]

Cardiovascular Mortality During the Course of the Study (up to 196 Days)

(NCT00596752)
Timeframe: During the course of the study (up to 196 days)

Interventionparticipants (Number)
Alprostadil11
Placebo14

[back to top]

Complete Healing of Ischemic Necroses and Ulcerations at 24 Weeks After the End of Study Drug Treatment

The assessment of ulcer area was collected per lesion with up to 2 lesions per subject (both legs could be affected). In the analysis a subject is only considered completely healed at a time point, if all ischemic lesions are reported as completely healed at that time point. (NCT00596752)
Timeframe: At 24 weeks after the end of study drug treatment

Interventionparticipants (Number)
Alprostadil108
Placebo103

[back to top]

Minor Amputations at 24 Weeks After the End of Study Drug Treatment

"Assessment of amputations was collected per leg affected by a lesion with up to 2 lesions per subject. Amputations were regarded as major if they were performed at the ankle joint level or above. Amputations of toes or part of the foot leaving a stump thereon the subject can walk were regarded as minor. An affected leg is defined as a leg with at least 1 lesion on Study Day -6 to -2 and only amputations of affected legs are considered in the efficacy analysis of amputations. A subject is counted as major/minor amputated, if at least 1 affected leg was major/minor amputated.~The number of subjects with minor amputation prior to or at 24 weeks after the end of study drug treatment is presented below." (NCT00596752)
Timeframe: At 24 weeks after the end of study drug treatment

Interventionparticipants (Number)
Alprostadil65
Placebo40

[back to top]

Revascularization Procedures at 24 Weeks After the End of Study Drug Treatment

The number of subjects with revascularization prior to or at 24 weeks after the end of study drug treatment is presented below. (NCT00596752)
Timeframe: At 24 weeks after the end of study drug treatment

Interventionparticipants (Number)
Alprostadil6
Placebo7

[back to top]

Cardiovascular Morbidity During the Course of the Study (up to 196 Days)

Cardiovascular morbidity is presented as number of subjects with myocardial infarction and/or stroke during the course of the study. (NCT00596752)
Timeframe: During the course of the study (up to 196 days)

,
Interventionparticipants (Number)
Myocardial infarctionsStrokes
Alprostadil53
Placebo63

[back to top]

Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment

The assessment of ulcer area was collected per lesion with up to 2 lesions per subject (both legs could be affected). In the analysis a subject is only considered completely healed at a time point, if all ischemic lesions are reported as completely healed at that time point. (NCT00596752)
Timeframe: At 12 weeks after the end of study drug treatment

,
Interventionparticipants (Number)
Stage 1 (n=253, n=251)Stage 2 (n=161, n=173)
Alprostadil4927
Placebo4330

[back to top]

Consumption and Type of Analgesic Medication During the Course of the Study (up to 196 Days)

The number of subjects who used analgesics are summarized for different time points/intervals during the course of the study. (NCT00596752)
Timeframe: During the course of the study (up to 196 days)

,
Interventionparticipants (Number)
Prior to treatment (n=414, n=424)Concomitant, Study Day 1 (n=414, n=424)Concomitant, Study Day 2 (n=414, n=424)Concomitant, Study Day 3 (n=413, n=424)Concomitant, Study Day 4 (n=412, n=423)Concomitant, Study Day 5 (n=411, n=423)Concomitant, Study Day 6 (n=411, n=423)Concomitant, Study Day 7 (n=409, n=422)Concomitant, Week 2 (n=409, n=422)Concomitant, Week 3 (n=399, n=416)Concomitant, Week 4 (n=393, n=404)Post treatment, Study Days 29-42 (n=348, n=354)Post treatment, Study Days 43-56 (n=361, n=370)Post treatment, Study Days 57-70 (n=361, n=346)Post treatment, Study Days 71-84 (n=352, n=344)Post treatment, Study Days 85-98 (n=341, n=339)Post treatment, Study Days 99-112 (n=321, n=318)Post treatment, Study Days 113-140 (n=309, n=301)Post treatment, Study Days 141-168 (n=306, n=304)Post treatment, Study Days 169-196 (n=272, n=271)
Alprostadil30029229529529229429029029225923817016415514614313212211898
Placebo31831431331731631131230630828425719117315514814012711710990

[back to top]

Increase/Decrease in Ulcer Area of ≥ 50 % at 24 Weeks After the End of Study Drug Treatment

In case of two ulcers the worse ulcer status is analyzed. The categories of investigator assessment are: complete healing, decrease by ≥ 50 %, unchanged, increase by ≥ 50 %. (NCT00596752)
Timeframe: At 24 weeks after the end of study drug treatment

,
Interventionparticipants (Number)
Complete healingDecrease by >= 50 %Remains unchangedIncrease by >= 50 %
Alprostadil101574530
Placebo98564830

[back to top]

Occurrence of Major Amputations at 24 Weeks After the End of Study Drug Treatment

Assessment of amputations was collected per leg affected by a lesion with up to 2 lesions per subject. Amputations were regarded as major if they were performed at the ankle joint level or above. Amputations of toes or part of the foot leaving a stump thereon the subject can walk were regarded as minor. An affected leg is defined as a leg with at least 1 lesion on Study Day -6 to -2 and only amputations of affected legs are considered in the efficacy analysis of amputations. A subject is counted as major/minor amputated, if at least 1 affected leg was major/minor amputated. (NCT00596752)
Timeframe: At 24 weeks after the end of study drug treatment

,
Interventionparticipants (Number)
Stage 1 (n=253, n=251)Stage 2 (n=161, n=173)
Alprostadil3220
Placebo4913

[back to top]

Systolic Pressure at Ankle Level at 24 Weeks After the End of Study Drug Treatment

Systolic pressure at ankle level was measured at the Arteria tibialis posterior and the Arteria dorsalis pedis. Two individual series of measurements of arterial pressures per subject across the assessed visits were selected for the analysis. For the first analysis (worst change analysis) the series of measurements in the one artery which has the worst change from Baseline at the final measurement was used. For the second analysis (worst value analysis) the series of measurements which has the worst final post-Baseline measurement was used. The series relevant for the analyses was selected from the series for the affected leg or legs only. The selection is 1 out of up to 4 series available per subject. Series without Baseline value and series with at least 1 measurement of more than 150 mmHg were excluded from the selection process due to the suspicion of media sclerosis of the lower limb artery. (NCT00596752)
Timeframe: At 24 weeks after the end of study drug treatment

,
InterventionmmHg (Mean)
Worst change analysisWorst value analysis
Alprostadil42.8339.39
Placebo39.4736.45

[back to top]

The Difference in Contrast Sensitivity Between Measurements at 3 Months After Intervention and Measurements at Baseline

Difference in contrast sensitivity was measured with the Pelli-Robson test, using a chart with letters arranged in groups of three. The first group has unit contrast and each subsequent group has a lower contrast. Passing a group means to read correctly at least two of the three letters. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents visual disability. (NCT00619229)
Timeframe: From baseline to 3 months

InterventionUnit on a scale (Mean)
Alprostadil0.084
Placebo-0.026

[back to top]

The Difference in Contrast Sensitivity Between Measurements at 6 Months After Intervention and Measurements at Baseline

Difference in contrast sensitivity was measured with the Pelli-Robson test, using a chart with letters arranged in groups of three. The first group has unit contrast and each subsequent group has a lower contrast. Passing a group means to read correctly at least two of the three letters. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents visual disability. (NCT00619229)
Timeframe: From baseline to 6 months

InterventionUnit on a scale (Mean)
Alprostadil0.028
Placebo0.009

[back to top]

The Difference in Contrast Sensitivity Between Measurements Immediately After Intervention and Measurements at Baseline

Difference in contrast sensitivity was measured with the Pelli-Robson test, using a chart with letters arranged in groups of three. The first group has unit contrast and each subsequent group has a lower contrast. Passing a group means to read correctly at least two of the three letters. A Pelli-Robson score of 2.0 indicates normal contrast sensitivity of 100 percent. Scores less than 2.0 signify poorer contrast sensitivity. Pelli-Robson contrast sensitivity score of less than 1.5 is consistent with visual impairment and a score of less than 1.0 represents visual disability. (NCT00619229)
Timeframe: From baseline to time immediately after intervention

InterventionUnit on a scale (Mean)
Alprostadil0.009
Placebo0.018

[back to top]

The Difference in Visual Acuity Between Measurements at 6 Months After Intervention and Measurements at Baseline

Difference in visual acuity was measured with the standard ETDRS chart with letters arranged in lines of five. The first line is assumed to have letters of a specific size and each subsequent line to consist of letters of a smaller size. The subject starts reading the first line and continues reading the following lines until failing a line. Passing a line means to name at least three of the five letters correctly. (NCT00619229)
Timeframe: From baseline to 6 months

InterventionLines read in ETDRS chart (Mean)
Alprostadil1.31
Placebo0.29

[back to top]

The Difference in Visual Acuity Between Measurements Immediately After Intervention and Measurements at Baseline

Difference in visual acuity was measured with the standard ETDRS chart with letters arranged in lines of five. The first line is assumed to have letters of a specific size and each subsequent line to consist of letters of a smaller size. The subject starts reading the first line and continues reading the following lines until failing a line. Passing a line means to name at least three of the five letters correctly. (NCT00619229)
Timeframe: From baseline to time immediately after intervention

InterventionLines read in ETDRS chart (Mean)
Alprostadil1.29
Placebo0.38

[back to top] [back to top]

Difference in Visual Acuity Between Measurements at 3 Months After Drug Intervention and Measurements at Baseline (Assessed Within Early Treatment Diabetic Retinopathy Study (ETDRS) Chart)

Difference in visual acuity was measured with the standard ETDRS chart with letters arranged in lines of five. The first line is assumed to have letters of a specific size and each subsequent line to consist of letters of a smaller size. The subject starts reading the first line and continues reading the following lines until failing a line. Passing a line means to name at least three of the five letters correctly. (NCT00619229)
Timeframe: From baseline to 3 months

InterventionLines read in ETDRS chart (Mean)
Alprostadil0.94
Placebo0.53

[back to top]

The Difference in Color Vision Between Measurements at 3 Months After Intervention and Measurements at Baseline

The difference in color vision after intervention in comparison to Baseline was assessed by the investigator as 'Changed from Normal to Pathologic', 'Finding unchanged', and 'Changed from Pathologic to Normal'. (NCT00619229)
Timeframe: From baseline to 3 months

,
InterventionParticipants (Number)
Changed from Normal to PathologicFinding unchangedChanged from Pathologic to Normal
Alprostadil1132
Placebo0143

[back to top]

The Difference in Color Vision Between Measurements at 6 Months After Intervention and Measurements at Baseline

The difference in color vision after intervention in comparison to Baseline was assessed by the investigator as 'Changed from Normal to Pathologic', 'Finding unchanged', and 'Changed from Pathologic to Normal'. (NCT00619229)
Timeframe: From baseline to 6 months

,
InterventionParticipants (Number)
Changed from Normal to PathologicFinding unchangedChanged from Pathologic to Normal
Alprostadil1123
Placebo0152

[back to top]

The Difference in Color Vision Between Measurements Immediately After Intervention and Measurements at Baseline

The difference in color vision after intervention in comparison to Baseline was assessed by the investigator as 'Changed from Normal to Pathologic', 'Finding unchanged', and 'Changed from Pathologic to Normal'. (NCT00619229)
Timeframe: From baseline to time immediately after intervention

,
InterventionParticipants (Number)
Changed from Normal to PathologicFinding unchangedChanged from Pathologic to Normal
Alprostadil1150
Placebo0134

[back to top] [back to top]

Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 2

The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance after Period 2 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From the end of 4 weeks of Interval Treatment (Period 2) to the end of 6-months Follow-up (Period 3)

Interventionmeter/meter (Mean)
Alprostadil1.18
Pentoxifylline1.17

[back to top]

Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings at Baseline

The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From Baseline to the end of 6-months Follow-up (Period 3)

Interventionmeter/meter (Mean)
Alprostadil1.89
Pentoxifylline1.99

[back to top]

Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at Baseline

The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 1 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From Baseline to the end of 4 weeks of Daily Treatment (Period 1)

Interventionmeter/meter (Mean)
Alprostadil1.58
Pentoxifylline1.58

[back to top]

Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings After Period 1

The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 2 divided by the pain-free walking distance after Period 1 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 4 weeks of Interval Treatment (Period 2)

Interventionmeter/meter (Mean)
Alprostadil1.25
Pentoxifylline1.24

[back to top]

Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline

The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 2 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From Baseline to the end of 4 weeks of Interval Treatment (Period 2)

Interventionmeter/meter (Mean)
Alprostadil2.60
Pentoxifylline1.98

[back to top]

Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 1

The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance after Period 1 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 6-months Follow-up (Period 3)

Interventionmeter/meter (Mean)
Alprostadil1.54
Pentoxifylline1.57

[back to top]

Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings After Period 2

The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance after Period 2 with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From the end of 4 weeks of Interval Treatment (Period 2) to the end of 6-months Follow-up (Period 3)

Interventionmeter/meter (Mean)
Alprostadil1.26
Pentoxifylline1.28

[back to top]

Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at Baseline

The ratio of pain-free walking distance was calculated by the pain-free walking distance after Period 3 divided by the pain-free walking distance at Baseline with determination of pain-free walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From Baseline to the end of 6-months Follow-up (Period 3)

Interventionmeter/meter (Mean)
Alprostadil2.27
Pentoxifylline2.36

[back to top]

Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 1

"Scores for subscales were calculated by summing non-missing item scores ranging from 1 (not at all; best possible outcome) to 4 (extremely; worst possible outcome) divided by the number of non-missing items. Hence each subscale score ranges from 1 (best possible outcome) to 4 (worst possible outcome). For subscales 'Mood' and 'Treatment expectation' five items each had to be reversed in order. Additionally, subjects were asked to assess their general health and quality of life on an ordinal scale between 0 (very good) and 10 (very poor).~Negative changes show a decrease from Baseline." (NCT01263925)
Timeframe: From Baseline to the end of 4 weeks of Daily Treatment (Period 1)

,
Interventionunits on a scale (Mean)
PainFunctional statusAnxietyMoodSocial lifeExpectation of treatmentState of general health during the last weekQuality of life during the last week
Alprostadil-0.24-0.21-0.16-0.07-0.05-0.00-0.51-0.37
Pentoxifylline-0.27-0.18-0.18-0.08-0.020.01-0.36-0.38

[back to top]

Changes in Quality of Life (as Measured With the PAVK 86 Questionnaire) From Baseline to the End of Period 3

"Scores for subscales were calculated by summing non-missing item scores ranging from 1 (not at all; best possible outcome) to 4 (extremely; worst possible outcome) divided by the number of non-missing items. Hence each subscale score ranges from 1 (best possible outcome) to 4 (worst possible outcome). For subscales 'Mood' and 'Treatment expectation' five items each had to be reversed in order. Additionally, subjects were asked to assess their general health and quality of life on an ordinal scale between 0 (very good) and 10 (very poor).~Negative changes show a decrease from Baseline." (NCT01263925)
Timeframe: From Baseline to the end of 6-months Follow-up (Period 3)

,
Interventionunits on a scale (Mean)
PainFunctional statusAnxietyMoodSocial lifeExpectation of treatmentState of general health during the last weekQuality of life during the last week
Alprostadil-0.28-0.26-0.20-0.06-0.090.07-0.43-0.36
Pentoxifylline-0.41-0.35-0.22-0.12-0.040.11-0.48-0.39

[back to top]

Ratio of Maximum Walking Distance After Period 1 in Comparison With the Findings at Baseline

The ratio of maximum walking distance was calculated by the maximum walking distance after Period 1 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From Baseline to the end of 4 weeks of Daily Treatment (Period 1)

Interventionmeter/meter (Mean)
Alprostadil1.39
Pentoxifylline1.43

[back to top]

Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings After Period 1

The ratio of maximum walking distance was calculated by the maximum walking distance after Period 2 divided by the maximum walking distance after Period 1 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 4 weeks of Interval Treatment (Period 2)

Interventionmeter/meter (Mean)
Alprostadil1.20
Pentoxifylline1.21

[back to top]

Ratio of Maximum Walking Distance After Period 2 in Comparison With the Findings at Baseline

The ratio of maximum walking distance was calculated by the maximum walking distance after Period 2 divided by the maximum walking distance at Baseline with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From Baseline to the end of 4 weeks of Interval Treatment (Period 2)

Interventionmeter/meter (Mean)
Alprostadil1.64
Pentoxifylline1.76

[back to top]

Ratio of Maximum Walking Distance After Period 3 in Comparison With the Findings After Period 1

The ratio of maximum walking distance was calculated by the maximum walking distance after Period 3 divided by the maximum walking distance after Period 1 with determination of maximum walking distances on the treadmill (12 % grade and 3 km/h). If a subject was not familiar with the treadmill, at least two test determinations were performed to accustom him/her to the treadmill. For all treadmill determinations the subject has been prevented from observing the treadmill display of the walking distance achieved. (NCT01263925)
Timeframe: From the end of 4 weeks of Daily Treatment (Period 1) to the end of 6-months Follow-up (Period 3)

Interventionmeter/meter (Mean)
Alprostadil1.39
Pentoxifylline1.42

[back to top]

Ease of IUD Insertion (Use of Ancillary Measures)

The primary outcome is the proportion in each group able to have the IUD inserted in a standard fashion without the ancillary measures of mechanical dilation of the cervix, placement of paracervical nerve block, or using abdominal ultrasound for guidance. The null hypothesis for the primary outcome is that misoprostol does not influence difficulty of insertion. (NCT01422226)
Timeframe: During the IUD insertion procedure, up to 2 hours

Interventionparticipants (Number)
Experimental Active Comparator1
Placebo Comparator2

[back to top]

Change in Oxygenation Index (OI)

Change in OI based on the arterial blood gases (ABG) measurements obtained at 60±15 minutes and ABG obtained 4±2 hours after start of study aerosol. (NCT01467076)
Timeframe: Measurement of ABG at 60±15 minutes and 4±2 hours after start of study aerosol.

Interventionoxygenation index (Mean)
Control4
Low Dose IPGE114
High Dose IPGE110

[back to top]

Change in Partial Pressure of Oxygen in the Blood (PaO2)

Changes in PaO2 based on the arterial blood gases (ABG) measurements obtained after 60 minutes and ABG obtained 4 hours after start of study aerosol. (NCT01467076)
Timeframe: Measurement of ABG at 60±15 minutes and 4±2 hours after start of study aerosol.

InterventionmmHg (Mean)
Control30
Low Dose IPGE185
High Dose IPGE148

[back to top]

Death

Deaths prior to discharge home. (NCT01467076)
Timeframe: From birth through status (death, transfer, or discharge).

InterventionParticipants (Count of Participants)
Control0
Low Dose IPGE10
High Dose IPGE10

[back to top]

Duration of iNO Therapy

Duration the infant is on INO from initial administration of INO to final discontinuation of INO. (NCT01467076)
Timeframe: From date of first administration of INO to date of final discontinuation of INO.

Interventionhours (Mean)
Control59.02
Low Dose IPGE118.57
High Dose IPGE156.22

[back to top]

Duration of Mechanical Ventilation

Duration the infant is on Mechanical Ventilation from birth through status (death, transfer or discharge) (NCT01467076)
Timeframe: From birth through status (death, transfer or discharge)

InterventionDays (Mean)
Control22
Low Dose IPGE18
High Dose IPGE116

[back to top]

Feasibility Assessed as the Number of Participants Who Were Enrolled in the Study

The primary outcome is the ability to recruit adequate number of infants (n=50) in a 9 month period without excessive (>20%) protocol violations. (NCT01467076)
Timeframe: From study start through 9 months after 75% of the participating sites are enrolling

Interventionparticipants (Number)
Control3
Low Dose IPGE12
High Dose IPGE12

[back to top]

Length of Hospital Stay

Length of stay in hospital from birth to discharge home. (NCT01467076)
Timeframe: From birth to discharge home

InterventionDays (Mean)
Control64
Low Dose IPGE131
High Dose IPGE139

[back to top]

Need for Extracorporeal Membrane Oxygenation (ECMO)

ECMO provided at the institution for the infant after discontinuation of study aerosol. (NCT01467076)
Timeframe: From after discontinuation of study aerosol through status (death, transfer, or discharge).

InterventionParticipants (Count of Participants)
Control2
Low Dose IPGE11
High Dose IPGE12

[back to top]

Need for Inhaled Nitric Oxide (INO) 72 Hours After INO

Administration of INO continued after the Infant was on INO for 72 hours (NCT01467076)
Timeframe: Date of first administration of INO to date of final discontinuation of INO

InterventionParticipants (Count of Participants)
Control1
Low Dose IPGE10
High Dose IPGE10

[back to top]

Number of Days of Supplemental Oxygen (O2) Used

Number of days from birth during which the FiO2 at some point was > 0.21. (NCT01467076)
Timeframe: From birth through status (death, transfer or discharge)

InterventionDays (Mean)
Control43
Low Dose IPGE18
High Dose IPGE111

[back to top]

Change in Neurobehavioral Symptom Inventory

Measures common symptoms after head injury. This scales ranges from 0-4 on 22 items, for a minimum score of 0 and a maximum score of 88. Higher scores mean a greater severity of symptoms. (NCT02615535)
Timeframe: baseline and six weeks

,
Interventionunits on a scale (Mean)
baseline6 weeks
EEG Neurofeedback-assisted Meditation35.227.7
Non-EEG Feedback-assisted Meditation33.124.6

[back to top]

Change in Percentage of EEG Activity Associated With Alpha, Beta, and Theta Rhythms as Measured by Surface Electrodes on the MUSE Device

"Change in percent Calm as determined by Muse device. Equations behind this algorithm to determine Calm are proprietary and were not shared by the device manufacturer. Ranges from 0% to 100%. Higher scores mean a better outcome." (NCT02615535)
Timeframe: baseline and at six weeks

,
Intervention"percentage of Calm" (Mean)
baselinesix weeks
EEG Neurofeedback-assisted Meditation49.757.7
Non-EEG Feedback-assisted Meditation3243.7

[back to top]

Change in Trail Making Test

Subjects are asked to sequence numbers and letters represented on a page as quickly as then can. Results are measured in seconds, ranging from 0 (hypothetically) to an infinite number (hypothetically). Results are scaled from 1 to 19. Lower scores mean a better outcome. (NCT02615535)
Timeframe: baseline and six weeks

,
Interventionunits on a scale (Mean)
baselinesix weeks
EEG Neurofeedback-assisted Meditation10.912.3
Non-EEG Feedback-assisted Meditation11.912.7

[back to top]

Change in Wechsler Adult Intelligence Scale-IV Digit Span

Tests participants digit span, repeating forward sequences of digits from 2 to 8. Scale ranges from 0 to 16. Higher scores mean a better outcome. (NCT02615535)
Timeframe: baseline and six weeks

,
Interventionunits on a scale (Mean)
baselinesix weeks
EEG Neurofeedback-assisted Meditation10.410.9
Non-EEG Feedback-assisted Meditation11.211.8

[back to top]

Change in Wechsler Adult Intelligence Scale-IV Digit Symbol Coding

A subject is provided with a key matching nine numbers to nine unique symbols. Numbers are then provided in random order and subjects have 120 seconds to match as many numbers with symbols as possible. All correct responses are scored. Scores range from 0 to 135. Scores are later scaled from 1 to 19. Higher scores mean a better outcome. (NCT02615535)
Timeframe: baseline and six weeks

,
Interventionunits on a scale (Mean)
baselinesix weeks
EEG Neurofeedback-assisted Meditation11.613.1
Non-EEG Feedback-assisted Meditation11.112.5

[back to top]

Change in Beck Anxiety Inventory

Subjects rate on a 0-3 likert scales responses to questions about anxiety. Scores range from 0-63. Lower scores mean a better outcome. (NCT02615535)
Timeframe: baseline and six weeks

,
Interventionscore on a scale (Mean)
baselinesix weeks
EEG Neurofeedback-assisted Meditation15.911.5
Non-EEG Feedback-assisted Meditation18.88.5

[back to top]

Change in Beck Depression Inventory-II

Subjects respond to questions on a Likert scale from 0-3 regarding depressive symptoms. There are 21 items. Scores range from 0-63. Lower scores mean a better outcome. (NCT02615535)
Timeframe: baseline and six weeks

,
Interventionscore on a scale (Mean)
baselinesix weeks
EEG Neurofeedback-assisted Meditation19.913.1
Non-EEG Feedback-assisted Meditation179.9

[back to top]

Change in Cognitive and Affective Mindfulness Scale-Revised

Subjects answer questions regarding mindfulness on a Likert Scale from 1-4. There are twelve questions total. Scores range from 4-48. Higher scores mean a better outcome. (NCT02615535)
Timeframe: baseline and six weeks

,
Interventionscore on a scale (Mean)
baselinesix weeks
EEG Neurofeedback-assisted Meditation24.227.3
Non-EEG Feedback-assisted Meditation24.728.3

[back to top]

the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI

the R2* value at the time after 14days of lipo-PGE1 intravenously minus the value at the baseline,R2* is a measure of the tissue content of deoxyhemoglobin. Which is inversely proportional to oxygen content in tissue (NCT02628106)
Timeframe: baseline and after 14days of lipo-PGE1 intravenously

Intervention1/ms (Mean)
Diabetic Nephropathy,Chronic Kidney Disease22.04

[back to top]